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ABSTRACT 
Prolidase has potential applications in cheese debittering, organophosphate detoxification 
and as an enzyme replacement therapy in prolidase-deficient patients. Recombinant Lactococcus 
lactis prolidases and their catalytic properties have previously been characterized in Dr. Tanaka's 
research group. Unlike other prolidases, L. lactis prolidase shows allosteric behaviour, metal-
dependent substrate specificity and substrate inhibition. The current project focuses on 
elucidating the three-dimensional structure of L. lactis prolidase using X-ray crystallography. 
Hexagonal plate-like crystals of wild-type L. lactis prolidase were grown by the hanging drop 
vapour diffusion method, allowing the crystals to grow to about 50 µm in their longest 
dimension. The crystallization cocktail in which they grew contained 0.08 M sodium cacodylate 
(pH 6.5), 0.16 M calcium acetate, 14 % PEG 8000 and 18 % glycerol. Crystal diffraction data 
was collected at a wavelength of 0.9795 Å on beamline 08ID-1 of the Canadian Macromolecular 
Crystallography Facility at the Canadian Light Source and was processed using X-ray Detector 
Software. The crystals belonged to space group C2 and estimated to contain three molecules in an 
asymmetric unit. The electron density map of this structure was solved by the molecular 
replacement method and the structure model was refined against 2.25 Å resolution data. Molecule 
A forms a dimer with molecule B, while molecule C forms a dimer with molecule C', which is 
located in the neighbouring crystal asymmetric unit. The electron density of molecule A was 
well-defined and complete. Therefore, all the 362 amino acid residues of L. lactis prolidase were 
fitted. The other two molecules were incomplete and less defined. Only 360 and 352 residues 
could be fitted in molecules B and C, respectively. Molecule C, the worst of the three, 
compromised the overall quality of the refined structure. However, the functional interpretation 
of the structure was not compromised since the well-defined molecules form a dimer with each 
other and the biologically-functional form of L. lactis prolidase is a homodimer. The final Rwork 
and Rfree are 22.39 and 27.77, respectively. Comparison with other known prolidases revealed that 
Asp 36 and His 38 are unique to L. lactis prolidase. These residues have been shown to be 
involved in the allosteric behaviour and substrate inhibition of this enzyme, respectively. 
Therefore, this crystal structure further supports their suggested contribution in L. lactis 
prolidase's unique catalytic properties.  
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1 INTRODUCTION 
The structure of proline is unique from the structures of the other 19 standard amino acids. 
Its side chain is connected to its nitrogen atom forming a cyclic structure (Figure 1.1). Trans 
conformation is preferred in most peptide bonds; however, a proline residue exists quite 
frequently in the cis conformation in peptides (Cunningham & O'Connor, 1997; Exarchos et al., 
2009; Yaron & Naider, 1993). Due to the unique features of proline, proline-containing peptides 
are less susceptible to hydrolysis by general peptidases. Therefore, they tend to be preferrably 
hydrolyzed by proline-specific peptidases. The hydrolysis of proline-containing dipeptides is 
performed by prolinase (EC 3.4.13.8) and prolidase (EC 3.4.13.9), which hydrolyze proline-
containing dipeptides with proline in the N- and C-terminal ends of the peptide bond, 
respectively.  
 
 
Figure 1.1 General structure of amino acids and the structure of proline. 
A: Side chain (R), amine group, carboxylic group and hydrogen are attached to an α-carbon. B: 
In proline, the side chain is connected to the amine group forming a cyclic structure. 
 
Prolidase has been isolated from mammalian tissues; including human liver, human kidney, 
human skin fibroblasts and human erythrocytes, and from microorganisms where it is involved in 
peptide metabolism (Fernandez-Espla et al., 1997; Ghosh et al., 1998; Wang et al., 2004). In 
humans, it is involved in the final stages of degradation of dietary proteins and in extracellular 
matrix collagen remodelling. Not only is this enzyme important in human physiology, but also it 
is involved in the liberation of amino acids in microbes needed for their growth. A typical 
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example of such importance in microbial activities is found in milk fermentation. Caseins, or 
milk proteins, are very rich in proline and therefore their degradation involves the action of 
proline-specific proteases and peptidases, including prolidase. Lactic acid bacteria (LAB) are 
often major strains used in milk fermentation, and they have a proteolytic system that is 
responsible for the liberation of free amino acids from casein and its hydrolytic products, 
including several proline-specific peptidases. Several other microbial species have been shown to 
require proline for their growth, such as Pyrococcus furiosus, of which growth declined when 
proline was removed from its growth media (Raven & Sharp, 1997). Prolidase has been isolated 
from P. furiosus (Ghosh et al., 1998). These findings suggest that prolidase plays a very critical 
role in the release of proline needed for growth by this bacterial species. 
Prolidase generally prefers substrates in which the N-terminal residue is non-polar, such as 
leucine, methionine, valine, phenylalanine and alanine (Ghosh et al., 1998; Yang & Tanaka, 
2008). It belongs to a class of enzymes called the "pita-bread'' enzymes, due to the pita-bread-like 
fold of the C-terminal domains of enzymes in this class. These enzymes are metalloenzymes and 
the amino acid residues coordinating the metal centers are conserved (Lowther & Matthews, 
2002). Other members of this class of enzymes include methionine aminopeptidase (MetAP: EC 
3.4.11.18) and aminopeptidase P (APP: EC 3.4.11.9). MetAP removes methionine from the N-
terminus of peptides in which the second residue is small and uncharged, while APP removes the 
N-terminal residue from peptides in which the second residue is proline. MetAP and APP prefer 
peptides with longer chains (at least three amino acid residues), unlike prolidase whose substrates 
are primarily dipeptides.  
Lactococcus lactis prolidase has been previously characterized in Dr. Tanaka's research 
group (Yang & Tanaka, 2008). This enzyme is a homodimer and each subunit is approximately 
40 kDa in size. Like other studied prolidases, it is a metalloenzyme and has specific activity 
towards Xaa-Pro peptides. Unlike other prolidases; it demonstrates allosteric behavior, substrate 
inhibition and metal-dependent substrate specificity. The most preferred substrate was Leu-Pro in 
the presence of Zn
2+
 and it changed to Arg-Pro when Zn
2+
 was replaced with Mn
2+
. The allosteric 
nature of this enzyme was indicated by sigmoidal curves for plots of enzyme catalytic rate against 
substrate concentration for both Leu-Pro and Arg-Pro (Yang & Tanaka, 2008). The sigmoidal 
curves suggest that the binding of one substrate or ligand molecule to the enzyme affects its 
affinity for other substrate or ligand molecules.  Dr. Tanaka's research group has conducted some 
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studuies to reveal the influence of specific residues on the functionality of this enzyme based on a 
amino acid sequence-based predicted model. However, the predicted model has its own 
limitations, and therefore the three-dimensional structure, i.e., X-ray crystallographic model is 
required to support their findings. 
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2 LITERATURE SURVEY 
2.1 Potential applications of prolidase 
2.1.1 Cheese ripening 
There are three major catabolic processes that are involved in flavor development during 
cheese ripening. These are lactose fermentation, lipolysis, and hydrolysis of milk caseins (van 
Kranenburg et al., 2002). The enzymes responsible for these processes are indigenously present 
in milk, present in LAB (starter and non-starter culture) and/or exogenously supplied during 
manufacturing (Wilkinson & Kilcawley, 2005). Among these, the most important flavor 
development process in hard-type and semi-hard-type cheeses is the degradation of milk caseins, 
which comprises protein degradation into polypeptides (proteolysis) and polypeptide hydrolysis 
into small peptides and free amino acids by peptidases (peptidolysis). During the degradation by 
LAB these hydrolytic processes are catalyzed by a cell wall-bound proteinase and several 
intracellular peptidases, respectively. The intracellular peptidases comprise endopeptidases, 
aminopeptidases, di-/tri-peptidases and proline-specific peptidases, including prolidase 
(Bockelmann, 1995). Another important step in LAB casein metabolism is the transport of 
peptides into the cell where the peptidases are located. This is done via di-/tripeptide transport 
system and/or the oligopeptide transport system depending on the bacterial strain (Kunji et al., 
1996; Liu et al., 2010). The proteolytic system of LAB is illustrated in Figure 2.1. Peptides from 
casein hydrolysis impart flavor to the fermented products, some of which may be undesirable, 
such as bitterness (Paul et al., 2014; Fallico et al., 2005). Also reported in the literature is the 
reduction in bitterness of cheese after further hydrolysis of the bitter peptides. In a study by 
Bockelmann (1995), a LAB starter strain with a high proteinase activity but low peptidase 
activity produced bitter-tasting milk, while the milk treated with strains with higher peptidase 
activity was not bitter. This suggests that a good balance between proteolysis and peptidolysis is 
critical for the development of flavor and the control of bitterness in fermented dairy products. 
The peptidase profile of a LAB strain used in cheese production influences its flavor and texture 
(Liu et al., 2010; Paul et al., 2014; van Kranenburg et al., 2002). Milk proteins (caseins) are rich 
in proline, leading to a higher occurrence of proline-containing peptides that are hard to 
hydrolyze. Proline-containing peptides have been shown to have a bitter taste (Ishibashi et al., 
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1988). Therefore, cheese can show the bitterness in the process and the importance of proline-
specific peptidases in this process cannot be overstated. Prolidase is one of such proline-specific 
peptidases and it is responsible for hydrolyzing the smallest proline-containing peptides (Xaa-
Pro). In addition to hydrolyzing proline dipeptides, prolidases generally prefer hydrophobic 
dipeptides. These prolidase substrates have been shown to exhibit higher levels of bitterness 
compared to the amino acid constituting them, that is, Xaa-Pro peptides are more bitter than Xaa 
and Pro alone (Ishibashi et al., 1988). Therefore, prolidase could be used to reduce bitterness of 
fermented dairy products. 
 
 
Figure 2.1 Illustration of the proteolytic system of Lactococcus lactis. 
Casein molecules are hydrolyzed by cell wall proteinase (PrtP). The oligopeptide (Opp) and the 
di-/tripeptide transport (DtpT) systems carry the resulting peptides into the cell where they are 
further hydrolyzed into smaller peptides and free amino acids by several intracellular peptidases. 
Dpp  = peptide-binding proteins (Adapted from Pinto et al., 2012). 
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2.1.2 Treatment of prolidase deficiency 
The extracellular matrix comprises different families of protein, and collagens are the most 
abundant among them. Their functions include providing structural support to the cells, 
regulating cell-to-cell communication and acting as storage for growth factors for the cells (Gelse 
et al., 2003). Collagens are rich in proline and hydroxyproline, with these residues making up to 
25 % of the amino acid residues in collagens (Phang et al., 2008). Hydroxyproline is formed by 
post-translational hydroxylation of proline and the added hydroxyl group is involved in 
intramolecular hydrogen bonding to provide mechanical strength to these proteins. Like other 
proline-rich proteins, collagens are resistant to hydrolysis by general proteases, such as pepsin, 
trypsin and chymotrypsin (Bruckner & Prockop, 1981). Therefore, they can only be hydrolyzed 
by specific collagenases and the resulting proline-rich peptides are hydrolyzed by several proline-
specific peptidases. Prolinase and prolidase are involved in the final steps of collagen breakdown 
for the release of free proline and other amino acids, which are then used for various functions 
such as protein synthesis and matrix remodelling (Figure 2.2). Lack of prolinase activity has not 
been associated with any disorder. On the other hand, lack of or reduced prolidase activity has 
been associated with a rare autosomal recessive disorder known as prolidase deficiency (Powell 
et al., 1974) caused by mutations in the prolidase gene. All of the reported mutations involve the 
residues in the C-terminal domain, which harbors the enzyme active site (Lupi et al., 2008). Its 
characteristic symptoms are skin ulcerations, recurrent skin infections, mental retardation and 
iminopeptiduria (Kikuchi et al., 2000; Klar et al., 2010; Lupi et al., 2004, 2006). The relationship 
between the clinical manifestations and the genotype is still poorly understood, probably due to 
the rarity of this disorder. Some of the adapted methods of treatment include oral 
supplementation with manganese, which is needed for prolidase activity, and topical treatment of 
the ulcers with proline and antioxidants. Although these have been reported to improve the skin 
lesions in some patients, they do not mitigate the molecular defects (i.e., they do not restore 
prolidase activity). It is not clear whether or not blood transfusion could treat prolidase 
deficiency. In one study, repeated apheresis erythroexchanges were performed in two prolidase-
deficient patients (Lupi et al., 2002). Although this did not improve their prolidase activity, it led 
to improvement of skin ulcerations and reduction of imidodipeptides in the patients' urine (Lupi 
et al., 2002). On the other hand, prolidase activity was detected when cultured fibroblasts from 
prolidase-deficient patients were incubated with liposomes loaded with prolidase from porcine 
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kidney (Perugini et al., 2005). This suggests that purified prolidase could potentially be used to 
treat prolidase deficiency. Gene therapy has also shown to be a viable option in treating prolidase 
deficiency (Ikeda et al., 1997). 
 
 
Figure 2.2 A schematic illustration showing prolinase and prolidase at the final stages of 
collagen breakdown.  
Xaa is any amino acid, while Pro and Hyp are proline and hydroxyproline, respectively (Adapted 
from Kurien et al., 2006 and Myara et al., 1984). 
 
2.1.3 Organophosphorus (OP) compounds detoxification 
2.1.3.1 What are organophosphorus compounds? 
The general structure of toxic organophosphorus compounds comprises a central 
phosphorus atom bonded to an oxygen or sulphur atom by a double bond and three other 
chemical constituents by single bonds (Figure 2.3). They are used as insecticides, pesticides and 
herbicides. Another group of organophosphorus compounds known as nerve agents finds use as 
chemical weapons and these have been used to attack humans during military conflicts and 
terrorist attacks. Nerve agents are considered the most lethal chemical warfare agents known. 
They belong to two main groups, G-agents and V-agents. The G-agents were first discovered by a 
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German scientist, Dr. Gerhard Schrader during his work on OP pesticides in the 1930's. This was 
followed by large-scale production of these compounds due to their importance in military. Some 
of the well-known nerve agents of the G-type include tabun (GA, ethyl-N,N-dimethyl 
phosphoramidocyanide), sarin (GB, isopropyl methyl phosphonofluoridate), cyclosarin (GF, 
cyclohexyl methyl phosphonofluoridate) and soman (GD, pinacolyl methyl 
phosphonofluoridare). The V-agents were synthesized after World War II through combined 
investigational efforts by US and British laboratories. Full scale production of VX (o-ethyl-S-(2-
diisopropylamino-ethyl)-methyl phosphonothiolate) started in 1961 (Szinicz, 2005).  
 
 
Figure 2.3 General structure of organophosphorus (OP) compounds. 
R1 and R2 can be alkyl, alkoxy or amine groups. X is a leaving group and may be attached to a 
phosphorus atom by oxygen or sulphur atom (Manco, 2008). 
 
Nerve agents were first used in warfare in the 1980's, including during the Iraq-Iran war 
during which sarin was used by the Iraqi armed forces (Macilwain, 1993). They were later used 
during terrorist attacks, including the two sarin attacks in Japan in 1994 and 1995. In 1994 this 
toxin was released in Matsumoto, a city of 200,000 residents. This led to 600 poisonings, 56 
hospitalizations and seven deaths (Suzuki et al., 1997 and Yanagisawa et al., 1995). The second 
sarin attack, which happened in 1995, was in Tokyo subway lines, after which more than 5,000 
victims required emergency medical attention. This attack led to twelve deaths, two of which 
happened on the day of the attack (Okumura et al., 1996, 2003). 
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2.1.3.2 Mechanism of OP toxicity 
Acetylcholine (ACh) is a neurotransmitter responsible for the transmission of nerve 
impulses at cholinergic, synaptic and neuromuscular junctions. It is released by the presynaptic 
neuron into the synaptic gap and interacts with acetylcholine receptor (AChR) on the 
postsynaptic membrane causing stimulation of the neuron. Neurotransmission is regulated by 
acetylcholinesterase (AChE, EC 3.1.1.7), which hydrolyzes acetylcholine into acetic acid and 
choline (Engelhard et al., 1967) and terminates neurotransmission. Organophosphorus 
compounds (OP pesticides and nerve agents) inhibit AChE by binding to the serine hydroxyl 
group in the enzyme active site. This phosphylation (inhibition) of AChE is similar to the 
acetylation of this enzyme by acetylcholine during its normal function. However, the breakdown 
of the acetylated acetylcholinesterase to release the free enzyme is more rapid than the 
breakdown of the inhibited acetylcholinesterase (Aldridge, 1950). Depending on the 
organophosphorus agent attached to AChE, a non-enzymatic time-dependent intramolecular 
rearrangement may result in the loss of an alkyl group from the phosphoryl group, known as 
"aging". This leads to the formation of an enzyme-organophosphorus moiety that is resistant to 
reactivation (Figure 2.4B), thus permanently inhibiting the AChE. OPs that undergo this 
rearrangement include soman, sarin, tabun and VX (Jokanović, 2009). Inhibition of AChE leads 
to accumulation of acetylcholine at nerve synapses and overstimulation of nerves, thereby 
paralyzing the functions of the human body. 
2.1.3.3 Current detoxification methods and their limitations 
Standard treatment of organophosphorus poisoning comprises antimuscarinic agents, 
cholinesterase reactivators and anticonvulsants. Antimuscarinic drugs, such as atropine, 
antagonize the effects of excess acetylcholine at end organs having muscarinic receptors. 
However, OPs do not only affect organs with muscarinic receptors, but also organs that have 
nicotinic receptors, such as muscles and respiratory organs. Therefore, these drugs do not address 
muscle weakness, twitching and respiratory depression that are caused by overstimulation of 
nicotinic receptors. Cholinesterase reactivators normally used are pralidoxime and obidoxime. 
They reactivate OP-inhibited AChE by binding to the phosphorus of the OP then liberating the 
enzyme. Although they have been used effectively to treat OP poisoning, their effectiveness 
depends on the structure of the OP involved (Worek et al., 2004).  
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Figure 2.4 Interaction of acetylcholinesterase (AChE) with its substrates and inhibitors. 
A: Hydrolysis of carboxyl esters (e.g. acetylcholine) by AChE (E-OH). The liberation of the 
enzyme is rapid. B: Inhibition of AChE (E-OH) by OPs. Spontaneous reactivation of the enzyme 
is very slow. Depending on the chemical nature of the OP the AChE-OP complex may undergo 
an irreversible loss of one of their alkyl groups, therefore, permanently inhibiting the enzyme 
(Adapted from Glynn, 1999). 
 
These two cholinesterase reactivators are ineffective against some nerve agents, including soman, 
tabun and cyclosarin. Also, some OPs age very rapidly and reactivation of AChE inhibited with 
these OPs using oximes is ineffective (Worek et al., 2004 and Worek et al., 2004). In addition to 
aging, some OPs, such as fenthion, are highly lipophilic and are stored in the adipose tissue and 
subsequently delivered into circulation even after administration of treatment drugs. Others have 
very low volatility and these are absorbed very slowly by human tissues. This absorption may 
continue several hours after exposure (Dalton et al., 2006). On the other hand, the currently used 
oximes (pralidoxime and obidoxime) are highly polar and are therefore short-lived in circulation 
(Eyer et al., 2007). Therefore, the treatment drugs are outlasted by these persistent OPs. Another 
limitation of oximes is that most of them are quaternary drugs with limited central nervous 
system (CNS) penetration and therefore, do not alleviate the central effects of poisoning 
(Yanagisawa et al., 2006). 
 
 11 
 
2.1.3.4 Prolidase as a method of OP detoxification 
Currently there are stockpiles of nerve agents that need to be destroyed. The traditional 
methods of destruction of chemical weapons, including nerve agents, involve the use of 
chemicals (Chauhan, 2008 and Yang, 1999). Large volumes of chemicals are required for this, 
therefore the chemical method is not economical. Also, the chemical treatment leaves behind 
byproducts that may be harmful to the environment (water, soil, air and animals exposed to 
them). While enzymes may not be applicable in treating OP-poisoned patients due to 
immunogenicity and limitations in delivery, they are a good potential in destructing stockpiles of 
OPs. Enzymatic methods are more efficient and more environmental-friendly than chemical 
methods. 
Organophosphorus acid anhydrolase (OPAA: EC 3.1.8.2) were originally isolated from 
Alteromonas species (Defrank & Cheng, 1991 and Cheng et al., 1993). Although their natural 
function in bacteria is unknown, these enzymes are capable of hydrolyzing toxic 
organophosphorus compounds. The sources of these enzymes do not have cholinesterases, that is 
acetylcholinesterase and butyrylcholinesterase, like insects and mammals. Therefore, it is 
unlikely that their natural function is to protect these organisms from organophosphorus 
poisoning. Comparison of the amino acid sequence of OPAA with the protein database has 
revealed a high level of similarity with prolidase. In addition to the structural similarity between 
these two enzymes, OPAA had prolidase activity (cleavage of dipeptides with proline in the C-
terminus position) (Cheng & Calomiris, 1996). Prolidase from different organisms have also 
demonstrated hydrolytic activity towards toxic organophosphorus compounds (Park et al., 2004). 
These findings suggest that OPAA is a prolidase whose natural role is peptide metabolism, but is 
also capable of detoxifying organophosphorus compounds. Therefore, several researches have 
focused on the structural and functional studies of prolidase as a potential enzyme for 
organophosphorus detoxification. This does not only include treating organophosphate poisoning, 
but also the destruction of stockpiles available worldwide (Kim & Lee, 2001). The prolidases of 
different origins have varying substrate and stereochemical specificities. Consequently, further 
studies are required to optimize their catalytic activity, which would require knowledge of their 
three-dimensional structures. 
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2.2 Protein X-ray crystallography 
X-ray crystallography finds application in rational drug design, genetic engineering of 
proteins and the study of biological systems, such as enzyme catalysis (Blundell et al., 2002; 
Kuhn et al., 2002; Minor, 2007). The flow diagram illustrating the experimental procedures 
undertaken during structure determination by X-ray crystallography is shown in Figure 2.5. The 
success of structure determination by X-ray crystallography depends on the ability to grow 
crystals of sufficient size and quality for X-ray diffraction. Therefore, crystallization is 
considered the rate-limiting step in X-ray crystallographic studies of macromolecules. 
 
 
Figure 2.5 Overview of the experimental procedures undertaken during protein X-ray 
crystallography (Adapted from Chayen & Saridakis, 2008 and Minor, 2007). 
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2.2.1 Purification 
The purity of a protein sample is very important not only in determining the success of 
crystallization, but also in the quality of the resulting crystal. This is because a crystal is a 
periodic arrangement of molecules into a three-dimensional lattice. Therefore, if the protein 
solution is not homogeneous, the foreign material may interfere with the packing of protein 
molecules into a crystal lattice. The more ordered the crystal lattice, higher the diffracting power 
of the crystal and hence the better the quality of the solved crystal structure (McPherson, 2004). 
2.2.2 Crystallization 
In a crystallization study the objective is to supersaturate the protein and initiate nucleation 
and crystal growth. When a protein is undersaturated it is fully-dissolved and will never 
crystallize. However, when it is supersaturated, nucleation or crystal growth may occur 
depending on the level of supersaturation. This can be explained by a crystallization phase 
diagram (Figure 2.6). Precipitating agents decrease the solubility of protein by interacting with 
water molecules making them unavailable to the protein molecules. When supersaturation is very 
high the protein precipitates and no crystal growth occurs. Moderate supersaturation is considered 
labile and in this supersaturation phase nucleation is favored. The level of supersaturation just 
below labile saturation is considered metastable and this is where crystal growth occurs.  
The two major steps during crystallization are screening and optimization. The former 
involves the identification of physical, chemical and biochemical conditions that may aid the 
growth of crystals, which may not necessarly be of sufficient quality for X-ray diffraction. These 
conditions include temperature, pH, precipitant type and protein concentration. There are 
commercial screen kits that have been formulated based on the conditions that have led to 
successful crystallization in the past. These screens are called sparse-matrix screens (Jancarik & 
Kim, 1991). The other kind of screens is called systematic screens (Brzozowski & Walton, 2001). 
Systematic screens sample the crystallization parameters in a rational way based on the properties 
of the protein sample under investigation. During optimization the conditions that give leads 
during the screening phase are further explored or fine-tuned to enhance the quality of the 
crystals for X-ray diffraction. These leads could be crystals of any quality, precipitates or any 
sign of phase separation. The conditions are screened and optimized using some of the available 
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crystallization techniques. These include dialysis, free-interface, microbatch and vapour 
diffusion. These explore the crystallization phase diagram differently as illustrated in Figure 2.6.  
Dialysis and free-interface diffusion methods are the least commonly used. In dialysis 
method, the protein solution and the crystallization solution are separated by a semi-permeable 
membrane, which allows the small molecules to move across down their concentration gradient. 
The  large molecules, on the other hand, are trapped on one side of the membrane. In free-
interface diffusion method, the protein solution and the crystallization are layered on top of each 
other in a capillary tube along which they gradually diffuse into each other (Salemme, 1972). 
Microbatch method involves simply mixing the protein solution with crystallization 
reagents. This is usually conducted in 72- or 96-well plates. Modification of the microbatch 
method involves covering the crystallization reagents-protein drop with low-density paraffin oil 
(0.87 g/ml) and this is known as microbatch-under-oil method (Chayen, 1997). The denser 
crystallization drop remains under the oil and the oil acts as a barrier to control or prevent 
evaporation and contamination of the drop by foreign material (Figure 2.7). However, the use of 
oil may limit the choice of reagents used since some of them may dissolve in it (Chayen, 1998). 
Supersaturation is achieved immediately since the initial protein concentration is the same as its 
final concentration. If the conditions are ideal nucleation occurs and is followed by a decrease in 
supersaturation, and hopefully crystal growth. 
In vapour diffusion method, 0.5 - 1 ml of the crystallization cocktail is pipetted into a well 
of a 24-well plate. Then, 1 - 10 µl is drawn from this reservoir and is mixed with the same 
volume of a protein solution and this drop is allowed to equilibrate against the crystallization 
cocktail in the reservoir through vapour exchange between them. This method is divided into the 
hanging drop and sitting drop vapour diffusion methods. In the hanging drop method, the 
crystallization drop is prepared on a siliconized cover glass. Grease is applied on the 
circumference of the well and the cover glass containing the crystallization drop is inverted over 
the well allowing the drop to hang over the sealed reservoir (Figure 2.8A). In the sitting drop 
method, the crystallization drop is prepared on a raised platform inside the well (Figure 2.8B). 
The well is also sealed to prevent evaporation. During vapour diffusion, the protein is fully 
dissolved or undersaturated at the beginning. Because the concentration of the precipitating agent 
in the drop is half the concentration in the well, there is evaporation of water molecules from the 
drop to the well (down their concentration gradient). 
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Figure 2.6 Protein crystallization phase diagram. 
The solubility curve is coloured red and the regions below and above this curve are 
undersaturation and supersaturation, respectively. The three levels of supersaturation are 
illustrated. The precipitation zone is the zone of high supersaturation where solutes (proteins) 
precipitate. The labile zone is the zone of moderate supersaturation where nucleation occurs. The 
metastable zone is the zone of slight supersaturation and this is where crystals grow. Green line 
represents dialysis method, blue line represents free-interface diffusion, brown line represents 
batch method and purple line represents vapour diffusion methods (Adapted from McPherson & 
Gavira, 2014; Chayen, 2004). 
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Figure 2.7 Illustration of microbatch-under-oil crystallization method. 
The crystallization drop consists of the crystallization cocktail and the protein solution and is 
covered with paraffin oil, which is less dense that the crystallization drop.   
 
This does not only lead to an increase in the concentration of the precipitant, but also that of the 
protein in the drop. This increase in protein concentration drives it to supersaturation. Ideally, if it 
is moderately supersaturated there will be formation of nuclei. When the protein molecules are 
used in nucleation there is less of them in solution, therefore, a drop in protein concentration. 
This will move the system from a labile nucleation zone towards a metastable zone where the 
crystals will grow.  
 
 
Figure 2.8 Illustration of vapour diffusion methods of crystallization. 
The crystallization drops consists of the crystallization cocktail and the same volume of the 
protein solution. A: The crystallization drop hangs over the reservoir on a siliconized cover glass. 
B: The crystallization drop "sits" on a platform. 
 
 17 
 
One of the major advantages of vapour diffusion over microbatch method is the fact that 
the crystallization conditions can be changed without disturbing the crystallization drop. The 
cover glass can be easily transferred to a well of different composition (Chayen, 2005) or the 
crystallization cocktail in the reservoir may be changed without touching the crystallization drop. 
On the other hand, the crystallization conditions remain constant during microbatch 
crystallization. This allows the experimenter to have control over the experimental conditions, 
which is not the case with diffusion-based methods during which diffusion leads to changes in 
crystallization parameters. 
High-throughput crystallization methods have been developed in order to speed up the 
crystallization step of X-ray crystallography. These methods allow for the screening of a wider 
range of conditions within a short period of time. They also allow for miniaturization of the 
reagents and the protein sample needed for crystallization (Bard et al., 2004; DeLucas et al., 
2003; Luft et al., 2003; Walter et al., 2005). At Oxford Protein Production Facility, the sitting 
drop vapour diffusion is conducted in 96-well plates using 100 nl of the reagents and of the 
protein solution (Walter et al., 2005). At Hauptman Woodward Research Institute, they use 200 
nl of each of the protein solution and the crystallization reagent under 5 µl of paraffin oil. A set 
up of 1536 wells is completed within 10 minutes (Luft et al., 2003). Technologies capable of 
employing as low as 20 nl of the reagents have also been developed (DeLucas et al., 2003, 2005). 
In addition to liquid handling and dispensing, image capturing, storing and analysis are 
automated at the high-throughput crystallization facilities (Bard et al., 2004; DeLucas et al., 
2003, 2005; Luft et al., 2003; Walter et al., 2005), which further reduces human intervention. The 
drawbacks of miniaturization include the growth of crystals that cannot be scaled up and the false 
negatives from conditions that would have otherwise produced crystals at larger cocktail volumes 
(Chayen & Saridakis, 2008). 
Sometimes only nucleation occurs, suggesting that the decrease in protein concentration 
was not adequate to drive the protein to metastable zone, where nuclei grow into large crystals. 
One may use these tiny crystals as seeds from which large crystals grow. The seeds are used in a 
system of lower supersaturation (metastable zone) since the aim is crystal growth rather than 
nucleation. This could be a lower protein concentration, lower precipitant concentration or even a 
lower temperature (Bergfors, 2003; D'Arcy et al., 2007; Gavira et al., 2011; McPherson & 
Gavira, 2014). An alternative to using the protein crystal as seeds is using different material, such 
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as minerals, glass charged or charged molecules (Fermani et al., 2001; Rong et al., 2002; 
Saridakis & Chayen, 2009; Tsekova et al., 1999). Too much nucleation may be due to the 
presence of dust or denatured protein particles in the protein solution. In order to address this, one 
may have to centrifuge or filter the protein sample through a 0.22 µm filter. On the other hand, 
this foreign material may be needed for nucleation and subsequent crystal growth. Therefore, it is 
recommended that filtering be done at the optimization stage to mitigate over nucleation rather 
than during the screening stage. Applying it during screening may result in passing out on the 
conditions suitable for crystal growth (Chayen & Saridakis, 2008). Another approach to address 
the issue of too much nucleation is intervening when nucleation has occurred and introducing the 
conditions suitable for enlargement of crystals, which are different from those required for 
nucleation. Some of the ways of achieving that include diluting the crystallization drop with 
protein-free buffer, transferring the crystallization drop to a reservoir of lower crystallization 
reagent concentration, and varying the incubation temperature. The latter finds application 
particularly in diffusion-based crystallization methods during which temperature determines the 
rate of diffusion and hence the rate of supersaturation of the protein sample. Another way of 
controlling the rate of supersaturation is by applying a layer of paraffin/silicon oil over a 
crystallization reservoir in vapour diffusion methods. This has been shown to slow down the 
crystallization process and lead to growth of larger crystals when compared to crystallization 
without an oil layer (Chayen, 1997). 
In addition to manipulating the crystallization conditions, one may need to modify the 
protein sample itself to enhance its crystallizability. This may involve removal of heterogeneous 
groups such as carbohydrates in glycoproteins, site-directed mutations and removal of flexible 
loop regions for which mobility may be responsible for lack of, or poor molecule packing during 
crystallization (Dale et al., 2003), and the use of affinity tags. 
2.2.3 X-ray data collection and processing 
Synchrotron radiation is the most common source of radiation for protein crystallography 
(http://biosync.sbkb.org/; accessed on April 5, 2015). A typical synchrotron beamline consists of 
three main components: a source of radiation, optical elements, and a detector (Dauter, 1996). 
The source may be a bending magnet or an insertion device. Both source types are available at 
the Canadian Light Source (08B1-1 and 08ID-1) and they constitute the Canadian 
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Macromolecular Crystallography Facility (Grochulski et al., 2011, 2012). Optical elements may 
include monochromators for selection of wavelengths, focusing mirrors and collimating slits. 
Most synchrotron beamlines are equipped with CCD-based detectors (Gruner & Ealick, 1995; 
Walter et al., 1995). These are very sensitive and fast, and therefore allow for collection and 
recording of both weak and strong reflections within a short period of time (Walter et al., 1995). 
Modern synchrotrons are superior to conventional laboratory X-ray sources due to primarily their 
high intensity and tunability. The latter finds application in collection of anomalous data, during 
which different wavelengths / energies are selected for optimization of the anomalous signal.  
One of the major drawbacks of the intense synchrotron radiation in X-ray crystallography is 
the radiation damage crystals undergo when collection diffraction data at room temperature. 
There are two types of radiation damage that crystals undergo during X-ray diffraction: primary 
and secondary damage. Primary radiation involves the interaction of the beam with the 
molecules, which generates heat and results in breakage of bonds and generation of free radicals. 
Secondary damage, on the other hand, is due to the diffusion of the free radicals and other 
reactive products through the crystal which cause damage at different areas of the crystal, 
including those which are not in direct contact with the beam. Primary radiation damage is dose-
dependent, while secondary radiation damage is time- and temperature-dependent (Garman, 
1999). Disulfide bonds, sulfur-containing residues and acidic residues, including aspartates and 
glutamates, have been shown to be more susceptible to radiation damage than other protein 
elements, suggesting that radiation damage is specific (Weik et al., 2000, 2001). Radiation 
damage to glutamates and aspartates may lead to decarboxylation of these residues (Weik et al., 
2001). Another factor that has been shown to influence the radiation sensitivity of proteins is the 
location of the residues in the structure: active site residues and the residues with more solvent 
accessibility tend to be more radiation sensitive that their buried counterparts (Burmeister, 2000; 
Weik et al., 2000, 2001). The latter are more exposed to radiolytic products of water, hydroxyl 
and hydrogen radicals, than the residues buried within the protein structure.  
Radiation damage is mitigated by collecting diffraction data at cryogenic temperatures 
(near 100 K), which minimizes secondary damage by the diffusion of reactive products. Prior to 
cooling the crystal with a cryogen it is treated with a cryoprotectant, which prevents the 
formation of ice in the crystal during cryogenic cooling. It does this by forming a vitreous glass 
layer around the crystal (Garman, 1999; Garman & Schneider, 1997). Just like crystallization 
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conditions, adequate cryoprotectant has to be determined and optimized. In some cases there may 
be ligands in the crystal and one may have to maintain the concentration of the ligand in the 
crystal during cryoprotection in order to make sure that the protein/crystal does not lose the 
ligand (Leif et al., 2003). The ligand may be needed for protein stability, structure solution and 
the interpretation of the protein function once the structure has been solved. Also, the method of 
cryoprotection has to be determined. One of them is soaking the crystal with a solution, usually 
the mother liquor, containing a cryoptotectant. Ideally, the cryoprotectant is included in the 
crystallization solution, which helps minimize crystal handling (Garman, 1999). With reduced 
radiation damage at cryo-temperatures usually a single crystal suffices for the collection of the 
entire data set. This is particularly important during multiple-wavelength anomalous dispersion 
(MAD) data collection during which a single crystal may be exposed to radiation dose for longer 
periods of time at multiple wavelengths. Collection of diffraction data from multiple crystals 
could mean more likelihood to introduce systematic errors, including non-isomorphism, and 
reduction of the chances to solve the crystal structure. Cryocrystallography also allows for safe 
storage and transport of crystals without them losing their diffraction quality. This allows 
efficient use of synchrotron beam lines whereby the crystals can be retrieved when beam time 
becomes available or when it is convenient for the crystallographer to do so (Garman & 
Schneider, 1997). However, cryocooling the crystals may lead to crystal lattice disorder, 
increased mosaicity (due to rapid temperature change), poor resolution, high B-factors and ice 
ring diffraction (Garman, 1999; Kriminski et al., 2002). This can be mitigated by crystal 
annealing, which involves warming the frozen crystal for a short period of time and then cooling 
it again (Kriminski et al., 2002; Hanson et al., 2003). This promotes crystal lattice relaxation. 
Advances in synchrotron radiation continue to make X-ray crystallography more robust. 
This includes the capability of some beamlines to be accessed remotely. Both beamlines of the 
CMCF, 08B1-1 and 08ID-1, at the Canadian Light Source are equipped with this technology 
(Grochulski et al., 2012). A laboratory information management system [MX Laboratory 
Information Virtual Environment (MxLIVE)] at the CMCF (Fodje et al., 2012) and other LIMS at 
other synchrotron facilities (Beteva et al., 2006; Delagenière et al., 2011; Gabadinho et al., 2010) 
allow for efficient management of data both on-site and off-site. 
The process of X-ray diffraction data collection involves: 1) mounting the crystal on the 
goniometer and aligning it along the X-ray beam, 2) characterization of the crystal to determine 
 21 
 
the strategy for data collection, and 3) implementing the optimum strategy for collection of the 
data (Winter & McAuley, 2011). The first step may be done manually, semi-automatically or 
automatically (Cipriani et al., 2006; Fodje et al., 2012; Pothineni et al., 2006; Ravelli et al, 2006). 
The second step involves collecting a few diffraction images and determining the characteristics 
of the crystal from these preliminary images; such as lattice type, unit cell dimensions and the 
presence of any crystal defects that may influence how the rest of the data should be collected for 
optimum quality. If the crystal is expected to contain a heavy atom and the experimenter 
considers collecting anomalous data, the characterization of the crystal will involve performing 
an excitation or a fluorescence scan, which reports on the elemental composition of the crystal. 
The crystallographer then determines the possible strategies for the collection of complete 
dataset. For example, for a high symmetry crystal a narrow total range of rotation may be 
sufficient to collect a complete data set, for example 45° total sweep for tetragonal symmetry. On 
the other hand, for a low symmetry crystal one may want to choose a wider rotation range, for 
example 180° for triclinic symmetry (Dauter, 1999). This is because symmetry-equivalent 
reflections have identical intensities and there are more of these in higher symmetry crystals than 
there are in lower symmetry crystals. The preliminary image analysis also helps determine the 
optimum exposure time. Exposure time should be long enough for collection of weak reflections, 
but not too long that the crystal ends up being overexposed to radiation dose leading to radiation 
damage. This analysis also helps determine the optimum crystal-detector distance to record all 
the reflections, including high resolution reflections at the edge of the detector. In case of 
potential defects, the experimenter determines whether it is worth going ahead with collection of 
the entire data set or if a different crystal needs to be examined. Possible crystal defects include 
twining, presence of ice rings and excessive mosaicity. For anomalous data collection the strategy 
would involve optimized X-ray wavelength(s) for optimum anomalous signal. 
The data is processed using some of the commonly used softwares, including XDS (Kabsch, 
2010), BEST (Popov & Bourenkov, 2003), HKL-2000 (Minor & Otwinowski, 1997), xia2 
(Winter, 2010). This involves indexing, during which the geometry of the crystal is determined. 
Diffraction data processing also involves integration, scaling and merging of the reflections. It is 
during the latter that symmetry-equivalent reflections are combined. Some of the parameters used 
to measure the quality of the diffraction data are resolution, signal-to-noise ratio, completeness, 
multiplicity and Rmerge. Resolution is the minimum distance between diffracting planes of a 
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crystal with the crystal still yielding diffraction data (Wlodawer et al., 2008). The smaller the 
spacing the more the reflections recorded, which means more data for structure solution and 
refinement. A complete data set is a data set in which all the reflections have been recorded. This 
is not always the case as crystals are very susceptible to radiation damage. Multiplicity is the 
average number of measurements for equivalent reflections. Rmerge is a measure of the agreement 
between equivalent reflections (Equation 2.1).  
 
Rmerge = Σh Σi│ <Ih> - Ih,i│ / Σh Σi Ih,i        (2.1) 
 
where h is the unique reflections and i is their symmetry-equivalent contributors. 
2.2.4 Structure determination 
Once the diffraction data has been collected, the next step is to calculate an electron density 
map from which the molecular model is built. The electron density map is a Fourier transform of 
structure factors, which are comprised of amplitudes and phases (Equations 2.2 and 2.3). The 
amplitudes are calculated from the intensities of reflections recorded during data collection. The 
phase information, on the other hand, is not recorded and has to be determined (Taylor, 2003). 
This is termed the "phase problem" in crystallography and structure determination is the 
determination of phase information needed to calculate the electron density map. 
 
Fhkl = │Fhkl│ e
iα
hkl         (2.2) 
 
ρ(xyz) = 1/V Σ│Fhkl│e
iα
hkl e
-2πi(hx + ky + lz)      
(2.3) 
 
where Fhkl are structure factors, │Fhkl│ are the amplitudes, αhkl are the phase angles for the 
reflections hkl and ρ(xyz) is electron density. The amplitudes, │Fhkl│, are derived from the 
intensities recorded during X-ray diffraction data collection (I α │Fhkl│
2
, where I are intensities 
of reflections). 
 
 Small molecules contain fewer atoms and diffract to higher resolution compared to large 
molecules, such as proteins. Phases of reflections in small molecules can be calculated from their 
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diffraction data alone based on strong reflections at certain regions of the unit cell. These 
methods of phase determination are called direct methods and they rely on estimation of phases 
of some reflections and using them to deduce the phases of the rest of the reflections (Cowtan, 
2001 and Taylor, 2003). For large molecules, on the other hand, this approach does not work. 
Additional experiments have to be conducted to determine the phases and these include 
molecular replacement, isomorphous replacement and anomalous dispersion. 
2.2.4.1 Molecular replacement 
This structure determination method requires the availability of a structure of a homologous 
model. Normally the minimum sequence identity required for a model to qualify to be used as a 
search probe is 25 % (Taylor, 2003). However, search models with varying sequence identities 
have been reported in the literature with varying successes (Scapin, 2013). This method of phase 
determination involves the rotation of the search model (homologous model) to determine its 
orientation with respect to that of the unknown in the crystal unit cell. The oriented model is then 
translated to determine its position relative to the position of the unknown in the crystal unit cell 
and if correctly rotated and translated it is placed in the crystal unit cell. Structure factors of the 
placed model are calculated and compared to those of the unknown structure. If they agree, the 
phases of the search model and amplitudes of the unknown (from the diffraction data) are used to 
calculate the electron density. There are several computer programs for searching molecular 
replacement solutions. These include Phaser (McCoy et al., 2007), SOMoRe (Jamrog et al., 
2005), AMoRe (Navaza, 1994; Navaza, 2001), MOLREP (Vagin & Teplyakov, 1997; Vagin & 
Teplyakov, 2010). Depending on the complexity of the problem one program may be superior to 
the other due to the fact that they use different algorithms. Some of the factors that determine the 
success of a molecular replacement search are the quality of the search model (for example; 
completeness, resolution, final refinement statistics prior to depositing, and presence of flexible 
regions or loops which may adopt different conformations), the quality of the diffraction data (for 
example, the size of the unit cell and the number of molecule copies in it), the level of similarity 
between the search model and the target protein. In some situations the search model may have to 
be manipulated to increase the chances of success of molecular replacement. These modifications 
may include side chain mutations and deletion of gaps based on the amino acid sequence 
alignment of the search model and the provided sequence of the unknown structure. Some of 
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these molecular replacement programs have these model preparation features incorporated in 
them already (Lebedev et al., 2008; Vagin & Teplyakov, 2010). 
2.2.4.2 Isomorphous replacement and anomalous dispersion 
Isomorphous replacement and anomalous dispersion are similar in the sense that they rely 
on the presence of atoms other than carbon, nitrogen and oxygen in a crystal. Also, these two 
methods do not require the availability of a homologous model. When heavy atoms (such as 
mercury and silver) are present in a crystal, the reflections will be more intense than the 
reflections of a protein crystal in which there are only carbon, nitrogen and oxygen atoms 
normally found in proteins. This is because there are more electrons in heavy atoms than there are 
in light atoms. Isomorphous replacement involves collection of a native data set and a heavy 
atom derivative data set(s). The former is collected from crystals without heavy atom 
introduction and the latter is a data set from a crystal in which a heavy atom has been introduced. 
The two crystals must be isomorphous so that the only difference between them is the intensity of 
reflections due to the heavy atom, hence the name isomorphous replacement. The difference 
between the intensities of reflections of the heavy atom derivative and those of the native crystal 
gives the intensities of reflections of the heavy atom. Direct methods can then be used to derive 
the position of the heavy atom, which is subsequently used to calculate the phase information of 
the native crystal and hence its electron density map. When a single derivative is used the method 
is called single isomorphous replacement and when more than one heavy atom derivatives are 
used it is called multiple isomorphous replacement. In addition to contributing more intense 
reflections than light atoms, the intensities of reflections of the Friedel pairs of heavy atoms are 
not equal. This is due to the fact that their electrons are more tightly bound to their nuclei than it 
is the case with light atoms. Heavy atoms are therefore, considered anomalous scatterers and their 
presence in protein crystals give anomalous signal during X-ray diffraction (Drenth, 2007). 
Similar to isomorphous replacement, the anomalous signal is used to determine the position of 
the heavy atom by direct methods and subsequently, the electron density map of the protein is 
calculated. The anomalous signal contributed by heavy atoms is wavelenghth-dependent. The 
method is called single-wavelength anomalous dispersion or multi-wavelength anomalous 
dispersion when diffraction data is collected at a single wavelength or mutiple wavelengths, 
respectively. 
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2.2.5 Model building, refinement and validation  
Model building involves fitting the polypeptide backbone and the side chains of the amino 
acid residues to the electron density map based on prior knowledge, such as amino acid sequence 
and the experimental data, that is the quality of the electron density map. In case of the electron 
density map calculated by molecular replacement, there will be some parts of the polypeptide 
backbone in the map already. Therefore, one may consider refinement before fitting the rest of 
the molecule in the map, and this may depend on the level of completeness of the model already 
built in the map. For the electron density map calculated by anomalous dispersion or 
isomorphous replacement, model fitting has to be started from the beginning. During refinement 
the aim is to find the closest agreement between the calculated and the observed structure factors 
by varying model parameters. The progress and the quality of the refinement strategy are 
normally monitored by the change in R-factors. These measure the deviation between the 
observed and calculated structure factor amplitudes (Fobs and Fcal; Equation 2.4) and a drop in 
these values indicate an improvement in the quality of the model. The two R-factors used are 
Rwork and Rfree. The former is calculated using the reflections used in refinement. During electron 
density map calculation and refinement a fraction of random reflections is set aside and is not 
used in these processes. These reflections are used to calculate Rfree and this serves as a cross 
validation tool that is used to ensure that the diffraction data is not over-interpreted (Brunger 
1992). In addition to the R-factors, geometrical parameters such as, bond lengths and angles are 
used to measure the quality of the refined model. Some of the programs used for this include 
Molprobity (Chen et al., 2010) and PROCHECK (Laskowski et al., 1993). 
 
R-factor = Σ│Fobs - Fcal│/ ΣFobs        (2.4) 
2.3 Crystal structures of prolidases 
Prolidases whose crystal structures have been solved include the ones from Pyrococcus 
furiosus (1pv9), Pyrococcus horikoshii (1wy2), and Thermococcus sibricus (4fkc). They are all 
homodimers with each subunit consisting of two domains, an N-terminal domain and a C-
terminal domain, linked by a helical linker. Their C-terminal domains contain the enzyme active 
site with two metal ions coordinated by two aspartic acids, two glutamic acids and one histidine 
residue (Jeyakanthan et al., 2009; Maher et al., 2004; Trofimov et al., 2012). The metal ions are 
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needed for the enzymes' catalytic activity. Prolidases from Pyrococcus species are activated by 
Co
2+
 and to a lesser extent Mn
2+
, whereas Zn
2+
 inactivates these enzymes (Ghosh et al., 1998; 
Jeyakanthan et al., 2009; Maher et al., 2004). The inhibitory effect of Zn
2+
 has been seen in 
prolidase from Lactobacillus delbrueckii and human liver as well (Stucky et al., 1995; Wang et 
al., 2005). Prolidases from Escherichia coli and humans prefer Mn
2+
 for full activity (Park et al., 
2004; Wang et al., 2005). However, Zn
2+
 and Mn
2+
 have been shown to co-exist in the metal 
center of human prolidase with the enzyme retaining partial activity (Besio et al., 2010). 
Mutations of the residues coordinating the metal center in P. furiosus prolidase lead to reduced 
activity when the residues mutated are responsible for coordinating only one of the metal atoms. 
The mutant in which the residue mutated coordinates both metal atoms does not show activity 
(Du et al., 2005). These findings on two prolidases from different organisms, human and P. 
furiosus, suggest that at least one of the metal sites has to be occupied by a preferred metal for 
some activity and both of them have to be occupied for full activity by this enzyme. 
The refined model of P. furiosus prolidase consists of a homodimer in the crystal 
asymmetric unit. However, its subunit A is more ordered than subunit B, which is missing some 
parts. The structure was solved with Zn in the metal center, which does not support enzyme 
activity (Ghosh et al., 1998 and Maher et al., 2004). This structure was solved at 2.0 Å resolution 
and the final Rwork and Rfree are 24 and 28, respectively (Maher et al., 2004). Like P. furiosus 
prolidase, the model of P. horikoshii  prolidase consists of a homodimer in the crystal 
asymmetric unit (Jeyakanthan et al., 2009). Unlike P. furiosus prolidase, both subunits are well-
defined and are of similar quality. In addition to the five amino acid residues coordinating the two 
Zn atoms in the metal center, a molecule of cacodylate is present next to the metal center and it is 
also involved in metal coordination. The structure was solved at 1.7 Å resolution and the final 
Rwork and Rfree are 18.7 and 21.0, respectively. The crystal structure of T. sibricus prolidase was 
solved at 2.6 Å resolution and the final Rwork and Rfree are 23.1 and 26.9, respectively (Trofimov et 
al., 2012). The structure was solved with two Cd atoms in the metal center.  
The most studied prolidase among these is P. furiosus prolidase. Maher et al. (2004) 
revealed that in P. furiosus prolidase a segment of subunit B (residues 36B - 39B) was close to 
the active site in subunit A and proposed that these residues may be involved in enzyme function, 
including substrate selection (Maher et al., 2004). Residues 36 - 39 are part of a loop structure in 
P. furiosus prolidase. Structure prediction model revealed that the loop structure (residues 32 - 
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43) is also present in L. lactis prolidase (Chen & Tanaka, 2011). However, in L. lactis prolidase 
the loop is longer and it contains charged amino acid residues, which are not present in P. 
furiosus prolidase. These residues are Asp 36, His 38, Glu 39 and Arg 40. This led to the 
hypothesis that the charged loop residues of L. lactis prolidase could be responsible for its unique 
characteristics (allosteric behaviour, metal-dependent substrate specificity and substrate 
inhibition). A mutant without the charged residues, Δ36 - 40, does not show enzyme activity. 
Therefore, the mechanisms of involvement of the charged loop residues could not be elucidated 
from this mutant, while the crucial influence of the loop is confirmed (Zhang et al., 2009). The 
Δ36 - 40 mutant, however, maintained other properties of the wild-type enzyme, including its 
dimeric conformation as evidenced by native-PAGE and gel filtration. Recent research has 
focused on trying to reveal the structural elements responsible for the unique catalytic properties 
of L. lactis prolidase using site-directed mutagenesis and computational modeling. Substitution of 
Asp 36 (Chen & Tanaka, 2011) and Arg 293 (Zhang et al., 2009) with serine (D36S and R293S) 
led to disappearance of allosteric behavior, suggesting that the negative charge of Asp 36 and the 
positive charge of Arg 293 are involved in the allosteric nature of the enzyme. This hypothesis 
was proven when a double mutant with the charges at these positions kept, D36E/R293K, 
maintained allosteric behavior of the wild-type enzyme; whereas, R293S mutant lost its allosteric 
behaviour (Zhang et al., 2009). Although substitution of His 38 (H38S) maintained activity, this 
mutant exhibited reduced substrate inhibition, suggesting that His 38 was involved in substrate 
inhibition. On the other hand, substitutions of Glu 39 and Arg 40 (E39S, D36S/E39S, R40S, 
R40K, R40E and H38S/R40S) led to loss of activity, suggesting that these two loop residues are 
needed for enzyme catalysis (Chen & Tanaka, 2011). These results all indicate the involvement 
of the predicted loop structure of residues number 32 - 43. However, the arguments are based on 
the predicted models and may not reflect the true structure of prolidase. 
 28 
 
3 HYPOTHESES AND OBJECTIVES 
It is hypothesized that knowledge of the three-dimensional structure of L. lactis prolidase 
will help elucidate the mechanism of its catalysis and thus contribute knowledge towards some of 
its potential applications. Structure determination will be aided by the availability of crystal 
structures of homologous models, which will be used as search models in molecular replacement. 
It is generally known that more stable macromolecules crystallize better than flexible 
macromolecules. Therefore, it was hypothesized the mutant in which some of the residues have 
been deleted (Δ36-40) may crystallize better than the wild-type prolidase, due to the presence of 
the longer flexible loop in the former. Also, since the dimeric conformation of wild-type 
prolidase were preserved in the Δ36-40 mutant, it was hypothesized that its crystal structure 
could also be used to interpret the functional properties of wild-type prolidase. Since L. lactis 
prolidase shows unique characteristics from other known prolidases, the three-dimensional 
structure should show the structural differences that result in the functional differences.  The 
objectives of the current study were, therefore, 1) to grow crystals of wild-type and 36-40 
mutant L. lactis prolidase and to solve their crystal structures by molecular replacement method; 
and 2) to interpret the functions of L. lactis prolidase based on the solved crystal structure. 
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4 MATERIALS AND METHODS  
4.1 L. lactis prolidase expression and purification 
Prolidase gene-containing Escherichia coli TOP10F' (Yang & Tanaka 2008) was cultured 
in 2 x 1.5 L Luria-Bertani (LB) broth (pH 7.0) at 17 °C. Prolidase expression was induced by 1 
mM isopropyl β-D-1-thiogalactopyranoside (IPTG) when an optical density of 600 nm was 0.5. 
The culture was allowed to grow at 17 °C for another 48 hours and the biomass was recovered by 
centrifugation (Sorvall Instruments Centrifuge; DuPont, Wilmington, DE, USA; Sorvall GSA 
rotor, 6000 rpm, 20 minutes, 4 °C). Purification of recombinant L. lactis prolidase was further 
optimized from what was previously described (Yang & Tanaka, 2008). In this thesis research it 
involved suspending harvested cells in 10-fold volume of 20 mM sodium citrate (pH 6.0)/ 1 mM 
manganese chloride. The cells were disrupted with a French press cell disruptor at 35 kPsi. The 
lysates were centrifuged at 11,000 rpm for 20 minutes yielding crude extraction of soluble 
proteins. The targeted recombinant protein was recovered by 60 % saturated ammonium sulfate 
precipitation. The protein was then dissolved in 3 ml of 20 mM sodium citrate (pH 6.0)/ 1 mM 
manganese chloride and dialyzed against 1 L of the same buffer at least three times. This was 
then loaded on DEAE anion exchange column (GE Healthcare DEAE Sephacel; Little Chalfont, 
Buckinghamshire, UK; 5 cm diameter × 20 cm), which was pre-equilibrated with the above-
mentioned buffer.  Prolidase was eluted with a 0 to 0.6 M sodium chloride linear gradient. 
Prolidase-containing fractions, as determined by SDS-PAGE (Figure 4.1), were combined and 
concentrated using an Amicon filtration unit (YM30; 30 kDa cut-off; Millipore, Billerica, MA, 
USA). The protein sample was filtered through a 0.2 µm filter and further purified using gel 
filtration chromatography (GE Health Science Superdex 200 10/300 GL; Little Chalfont, 
Buckinghamshire, UK; 24 ml). Two hundred and fifty microlitres of concentrated protein sample 
was loaded on the column and eluted with 20 mM sodium citrate (pH 6.0), 1 mM manganese 
chloride, 0.15 M sodium chloride and 15 % glycerol at a flow rate of 0.25 ml/min. Prolidase-
containing fractions from this step were identified on SDS-PAGE. The chromatogram and the 
SDS-PAGE diagram from this purification step are shown in Figures 4.2 and 4.3, respectively. 
The prolidase-containing fractions were combined and concentrated using centrifugal devices 
(Microsep Advance Centrifugal Devices; Pall Corporation, Ann Arbor, MI, USA; 10 kDa cut-
off). The concentration and purity were determined by the Bradford method and by the presence 
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of a single band on SDS-PAGE, respectively. The same procedure was followed for both wild-
type and 36-40 mutant L. lactis prolidase. Prior to crystallization the protein solution was 
diluted to the desired concentration using 2 mM sodium citrate (pH 6.0)/ 1 mM manganese 
chloride, which had been filtered through a 0.2 µm filter. The protein solution was also filtered 
and/or centrifuged at 14,000 rpm for 5 minutes to remove any foreign material and denatured 
proteins. 
 
  
Figure 4.1 SDS-PAGE showing wild-type L. lactis prolidase fractions from DEAE anion 
exchange chromatography. 
"M" is molecular weight marker and the numbers represent the fraction numbers. Fractions 53 - 
59 are wild type prolidase-containing fractions that were chosen for further purification. 
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Figure 4.2 Size exclusion chromatogram of wild type L. lactis prolidase. 
The eluent buffer comprised 20 mM sodium citrate (pH 6.0), 1 mM manganese chloride, 0.15 M 
sodium chloride and 15 % glycerol. 
 
  
Figure 4.3 SDS-PAGE showing wild-type L. lactis prolidase fractions from size exclusion 
chromatography. 
"M" is molecular weight marker and the numbers represent the fraction numbers. The fractions 
that were combined and concentrated are 52 - 55, 59 - 63 and 69 - 72. 
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4.2 Crystallization 
4.2.1 Screening 
Hampton Research screens HR2-110 and HR2-112 (Tables A1 and A2) were used as the 
initial screens for crystallization using the hanging drop vapour diffusion method. Reagents 25 
and 27 of HR2-110 were not used since they are known for not producing crystals. Therefore, the 
total number of reagents used was 96. The starting concentration was 10 mg/ml for both wild 
type and 36-40 mutant L. lactis prolidase solutions. Two identical set ups were carried out in 
24-well plates, one at room temperature and the other at 4 °C. The crystallization drops consisted 
of 2 µl of the reservoir solution and 2 µl of the protein solution during initial screening. 
In order to investigate a wider range of conditions, a purified wild-type L. lactis prolidase 
solution was sent to Hauptman-Woodward Research Institute for automatic high-throughput 
screening. The method used was microbatch-under-oil and 1536 reagents were screened. This 
involved mixing 200 nl of the protein sample with the same volume of the crystallization 
screening reagent and covering the drop with paraffin oil. Image capturing and recording was 
done a day after setting up and weekly after for a total period of six weeks. The detailed 
procedure followed is explained in Luft et al. (2003) 
4.2.2 Optimization 
The conditions that produced any form of crystals, including microcrystals, needles and 
plates, from Hampton screens were optimized. Optimization involved varying temperature, 
protein concentration, concentrations of the screening reagents, the pH of the buffer, and 
substituting metal salts in screening reagents with different ones. The same crystallization 
method, hanging drop vapour diffusion, was used during optimization.  
For high-throughput screening only conditions that produced three-dimensional and 
symmetrical crystals were selected for optimization. Both hanging drop vapour diffusion and 
microbatch under oil methods were used to set up these optimization experiments. The latter was 
performed in 72-well microbatch plates by mixing 1 µl of the protein solution with 1 µl of the 
protein solution and covering the drop with paraffin oil. This is illustrated in Figure 4.4. 
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Figure 4.4 An illustration of the steps taken when setting up a microbatch-under oil 
crystallization experiment.  
A: A 72-well microbatch plate used to prepare the setup. B: 1 µl of the crystallization cocktail 
was added to 5 replicate experiment wells. C: The same volume of a protein solution was by 
touching the pipette tip to the cocktail drop and dispensing the solution to each of the 
experiments.  D: 20 µl of paraffin oil (PX0045-3; EMD Chemicals, Darmstadt, Germany) was 
added to each well. An additional 5 ml of paraffin oil was used to cover all the wells once all the 
drops had been set up. 
 
Co-crystallization was done by including solutions of proline, proline + leucine, proline + 
arginine and proline + phenylalanine in the crystallization reagents and/or the crystallization 
drops. The criterion for co-crystallant selection was based on the preference of prolidase for Leu-
Pro and Arg-Pro as substrates and its preference for substrates with hydrophobic residues at the 
N-terminal end of the dipeptide, such as Phe-Pro (Yang & Tanaka, 2008). 
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4.3 X-ray diffraction 
Diffraction data was collected at a wavelength of 0.9795 Å on beamline 08ID-1 of the 
Canadian Macromolecular Crystallography Facility at the Canadian Light Source (CLS) 
(Grochulski et al., 2011). The crystals were individually scooped out of the crystallization 
cocktail using a loop and immediately immersed and cooled in liquid nitrogen. Additional 
cryoprotection was not considered since the crystallization solution contained 12 - 15 % PEG, 
which acts as a cryoprotectant. They were then rapidly transferred from the liquid nitrogen and 
mounted on a goniometer, under a stream of gaseous nitrogen, using a cryotong. Prior to 
collecting the entire data set, about 10 frames were collected and processed to characterize the 
crystal and determine the optimum strategy for the collection of diffraction data. In order to 
determine the elemental composition of the crystal and the surrounding mother liquor, X-ray 
fluorescence scanning was performed. 
4.4 Structure determination 
The amino acid sequence of L. lactis prolidase was used to search for the templates to be 
used in molecular replacement. The search models found in the Protein Data Bank with the 
highest amino acid sequence identities were prolidases from P. furiosus (1pv9) and P. horikoshii 
OT3 (1wy2). They both had 37 % amino acid sequence identity with L. lactis prolidase. Based on 
amino acid sequence alignments, the similarities at the N-terminal ends were lower compared to 
those at the C-terminal ends of the sequences (Figure 4.5). Therefore, a better match for the first 
122 residues was searched for and was found to be Streptococcus pneumoniae proline dipeptidase 
(3pn9), which comprises 138 amino acid residues. It showed 43 % amino acid sequence identity 
with the N-terminal end (residues 1 - 122) of L. lactis prolidase. When using the remaining 
residues of L. lactis prolidase (residues 123 - 362), the sequence identity with P. horikoshii 
prolidase increased to 45 %. Therefore, S. pneumoniae prolidase and the C-terminal domain 
(residues 125 - 351) of P. horikoshii prolidase were selected as molecular replacement search 
templates. Model preparation involved removing the ligands they were solved with (including 
water molecules, metal atoms and crystallization solvents) and converting them to polyalanine 
peptides in PHENIX (Adams et al., 2010). Molecular replacement was performed using Phaser 
(McCoy et al., 2007), which is also in PHENIX suite.  
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Figure 4.5 Amino acid sequence alignments of L. lactis prolidase (Llprol) with P. horikoshii 
(Phprol, 1wy2) and P. furiosus prolidase (Pfprol, 1pv9). 
Identical and similar residues are highlighted green and marked with "+", respectively. The 
residues in the N-terminal ends of the prolidase sequences are less identical than the residues in 
the C-terminal ends. Alignments were performed using Basic Local Alignment Search Tool 
(Altschul et al., 1997). 
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4.5 Model building, refinement and validation 
The molecular replacement solution was refined against the diffraction data in PHENIX 
(Adams et al., 2010). The protein residues were fitted in the electron density map using Coot 
(Emsley et al., 2010) for visual display, followed by real space refinement. Refinement strategies 
employed at the beginning included: rigid body, xyz, occupancies, individual B-factors, 
simulated annealing and NCS-restraints refinements. After fitting the polypeptide chains, the 
ligands were fitted from Coot library. Metal ion coordination and ligand restraints were generated 
using ReadySet implemented in PHENIX, which uses electronic Ligand Builder and Optimization 
Workbench (eLBOW) to generate ligand restraints (Moriarty et al., 2009). Water molecules were 
added automatically during refinement in PHENIX. The strategies employed towards the end of 
refinement included optimization of X-ray/stereochemistry and X-ray/ADP weights. Refinement 
was alternated with manual corrections of the model in Coot. The final refinement run was done 
using REFMAC5 (Murshudov et al., 1997), incorporated in CCP4 program suite (Winn et al., 
2011) and the refinement statistics table was compiled in PHENIX. 
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5 RESULTS  
5.1 Crystallization 
5.1.1 Screening 
The crystallization screening results from both in-house hanging drop vapour diffusion 
setups are summarized in Table 5.1 and Figure 5.1. All successful conditions included PEG 8000 
as the precipitant and sodium cacodylate as the buffer (Table 5.1). The crystallization screening 
results from high-throughput microbatch-under-oil are illustrated in Figure 5.2. In addition to the 
conditions consisting of PEG 8000 and sodium cacodylate producing crystalline material, more 
chemical reagents were successful at growing large three-dimensional and/or symmetrical 
crystals, including a variety of PEGs (Figure 5.2).  
 
Table 5.1 Hampton Research reagents that were selected for optimization and the 
description of the crystalline material they produced. 
Reagent formulation Description of the crystals grown during 
screening 
20 % (w/v) polyethylene glycol 8000, 0.1 M 
sodium cacodylate trihydrate (pH 6.5), 0.2 M 
magnesium acetate trihydrate 
Rod clusters and single three-dimensional 
crystals 
30% (w/v) polyethylene glycol 8,000, 0.1 M 
sodium cacodylate trihydrate (pH 6.5), 0.2 M 
sodium acetate trihydrate 
Plate- and rod-like crystals, as well as three-
dimensional crystals 
18% (w/v) polyethylene glycol 8,000, 0.1 M 
sodium cacodylate trihydrate (pH 6.5), 0.2 M 
zinc acetate dihydrate 
Plate-like (two-dimensional) crystals 
18% (w/v) polyethylene glycol 8,000, 0.1 M 
sodium cacodylate trihydrate (pH 6.5), 0.2 M 
calcium acetate hydrate 
Plate-like (two-dimensional) crystals 
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Figure 5.1 Needle-shaped and microcrystals obtained using Hampton Research 
crystallization reagents during in-house screening by the hanging drop vapour diffusion 
method. 
These were obtained from crystallization solutions comprising PEG 8000, sodium cacodylate (pH 
6.5) and 0.1 M manganese chloride. 
 
5.1.2 Optimization 
The conditions that produced crystals from optimizing Hampton Research screens were 0.1 
M sodium cacodylate (pH 6.5), 12 - 16 % PEG 8000 and 0.1 M manganese chloride at 20 ºC and 
room temperature (~25 ºC). Some of the crystals were bipyramidal in shape and about 250 µm in 
size (Figure 5.3). Others grew as long rods, rod clusters and twins. Optimization of the conditions 
from high-throughput screening using both the hanging drop vapour diffusion and microbatch 
under oil crystallization methods led to the growth of hexagonal plate-like crystals. However, the 
hanging drop method was preferred since the crystals floated in the crystallization drop and were 
easily scooped out during harvesting. On the other hand, crystals grown using the microbatch-
under-oil method stuck to the bottom of the 72-well plate and were easily broken during 
harvesting. Thus, the diffraction data was only collected from the crystals from the hanging drop 
vapour diffusion method. Successful crystal growth was done in 0.08 M sodium cacodylate (pH 
6.5), 0.16 M calcium acetate, 11 - 16 % PEG 8000, and 17 - 21 % glycerol. 
 39 
 
 
 
Figure 5.2 Three-dimensional and/or symmetrical crystals from high-throughput screening 
grown using microbatch-under-oil method. 
Each crystallization drop consisted of 200 nl of 10 mg/ml wild-type L. lactis prolidase and 200 nl 
of the crystallization reagent. The reagents were A: 0.1 M ammonium nitrate, 0.1 M tris (pH 8), 
24% PEG 20000; B: 0.1M lithium chloride, 0.1M tris (pH 8), 20% PEG 8000; C: 0.1M 
ammonium thiocyanate, 0.1M tris (pH 8), 20% PEG 8000; D: 0.1 M calcium acetate, 0.1 M bis-
tris propane (pH 7), 20% PEG 4000; E: 0.16 M calcium acetate hydrate, 0.08M sodium 
cacodylate trihydrate (pH 6.5), 14.4% PEG 8000, 20% glycerol; F: 0.2M calcium chloride 
dihydrate (pH 5.1), 20% PEG 3350; G: 0.8M lithium sulfate monohydrate, 0.1M bis-tris propane 
(pH 7) and H: 1.5M lithium sulfate monohydrate, 0.1M tris (pH 8.5). 
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These conditions yielded plate-like hexagonal crystals (Figure 5.4), and interestingly, these 
conditions are very similar to the conditions that produced bipyramidal crystals (Figure 5.3). The 
same conditions that successfully yielded crystals of wild-type L. lactis prolidase also yielded 
large three-dimensional crystals of 36-40 mutant L. lactis prolidase. However, 36-40 crystals 
cracked and therefore, could not be used for X-ray diffraction. Representative crystals of 36-40 
mutant L. lactis prolidase are illustrated in Figures 5.5. Co-crystallization with prolidase 
hydrolytic products, amino acids, was also successful. However, preliminary analysis of the 
diffraction data suggested that the crystals were not of sufficient quality for X-ray diffraction. 
 
  
 
Figure 5.3 Crystals of wild type recombinant L. lactis prolidase grown using the hanging 
drop vapour diffusion method.  
A: The drop consisted of 3 µl of the reservoir solution and 2 µl of 5 mg/ml wild type L. lactis 
prolidase. The reservoir solution comprised 15 % (w/v) PEG 8000, 0.1 M sodium cacodylate (pH 
6.5) and 0.1 M manganese chloride. The set up was incubated at 20 ºC for 10 days. B: The drop 
consists of 2 µl of the reservoir solution and 2 µl of 5 mg/ml prolidase solution. The reservoir 
contained the same reagents as A, but the level of PEG 8000 was 12 % instead of 15 % (w/v). 
The set up was incubated at room temperature (~25 ºC) for 10 days.  
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Figure 5.4 Crystals of wild type recombinant L. lactis prolidase grown in the presence and 
the absence of reaction products using the hanging drop vapour diffusion method. 
A: The crystal drop comprised 2 µl of 5 mg/ml prolidase solution, 2 µl of the reservoir solution 
and 0.2 µl of 100 mM arginine. The reservoir comprised 0.16 M calcium acetate, 0.08 M sodium 
cacodylate (pH 6.5), 12 % PEG 8000, 20 % glycerol and 10 mM proline. The set up was 
incubated at 20 ºC for 10 days. B: The crystallization drop comprised 2 µl of 5 mg/ml prolidase 
solution and 2 µl of the reservoir solution. The reservoir solution comprised 0.16 M calcium 
acetate, 0.08 M sodium cacodylate (pH 6.5), 14 % PEG 8000 and 18 % glycerol. The set up was 
incubated at room temperature (~25 ºC) for 10 days. These crystals were used for structure 
solution. 
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Figure 5.5 Crystals of 36-40 mutant recombinant L. lactis prolidase grown using the 
hanging drop vapour diffusion method. 
A: The drop comprised 1 µl of 5 mg/ml prolidase solution, 1 µl of the reservoir solution and 0.2 
µl of 100 mM leucine. The reservoir solution comprised 0.16 M calcium acetate, 0.08 M sodium 
cacodylate (pH 6.5), 15 % PEG 8000, 20 % glycerol and 10 mM proline. The set-up was 
incubated at 23 °C for 10 days. B: The drop comprised 2 µl of 5 mg/ml prolidase solution and 2 
µl of the reservoir solution. The reservoir solution comprised 0.1 M calcium acetate, 0.1 M 
sodium cacodylate (pH 6.5) and 16 % PEG 8000. The set-up was incubated at 20 ºC for 10 days.  
 
5.2 X-ray diffraction 
The bipyramidal crystals produced from Hampton Research leads yielded 2.35 Å resolution 
and they belonged to space group P1. There was an estimate of six molecules in an asymmetric 
unit of the crystal. In addition to lack of symmetry and a high number of molecules in the crystal 
asymmetric unit, partial twinning was observed. This suggests that the large crystals grown were 
in fact multiple crystals that had grown on top of each other. Thus, the reflections recorded 
during X-ray diffraction data collection were from multiple crystals rather than a single crystal. 
The quality of the diffraction data was, therefore, low and determination of the three-dimensional 
structure of L. lactis prolidase using this data was not successful. On the other hand, the 
hexagonal crystals grown from high-throughput screening leads yielded 1.93 Å resolution data 
and they belonged to space group C2. There were three molecules in the crystal asymmetric unit. 
This data was of better quality than the former and was successfully used to determine the three-
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dimensional structure of wild-type recombinant L. lactis prolidase. The data collection statistics 
from both crystal types are summarized in Table 5.2 for comparison. 
  
Table 5.2 Data collection statistics from the first crystals of wild type L. lactis prolidase. 
Crystal description Bipyramidal Hexagonal 
Space group P1 C2 
Unit-cell parameters (Å, °) a = 81.27, b = 84.76,  
c = 100.47, α = 73.68,  
β = 69.01, γ = 89.91 
a = 212.13, b = 76.99  
c = 88.92, α = γ = 90,  
β = 112.39 
Molecules per asymmetric unit 6 3 
Resolution (Å) 2.35 1.93 
{I/σ (I)} 10.96 6.28 
Completeness (%) 97.80 99.8 
Unique reflections 97414 99362 
Multiplicity 3.9 3.8 
R merge  7.7 12.1 
 
5.3 Structure determination and refinement 
Molecular replacement program, Phaser, found a solution of three molecules in the crystal 
asymmetric unit. After fitting polypeptide residues and several rounds of refinement there were 
two blobs of positive electron density around Asp 221, Asp 232, His 296, Glu 325 and Glu 339, 
suggesting that some ligands were missing. In other prolidases the metal cluster is coordinated by 
the same amino acid residues, i.e. two aspartic acids, two glutamic acids and a histidine residue 
(Jeyakanthan et al., 2009; Maher et al., 2004; Trofimov et al., 2012). Accordingly, two 
manganese atoms were fitted per chain since manganese salt was used in the purification buffer. 
However, there was still positive electron density after fitting two manganese atoms, suggesting 
that another ligand present in the crystal was missing in the model (Figure 5.6). X-ray 
fluorescence scan suggested that there was arsenic in the sample (Figure 5.7). Since cacodylate 
used in the crystallization cocktail is an organic molecule of arsenic ((CH3)2AsO2H), cacodylate 
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was fitted in the third site of the metal center. The crystal structure of P. horikoshii OT3 prolidase 
(1wy2) has also been solved with a cacodylate ion in the metal cluster of the structure.  
The refined model of L. lactis prolidase consists of three molecules (chains A, B and C) in 
the asymmetric unit (Figure 5.8). In chain A, all the 362 molecules were fitted while in chains B 
and C the electron densities were disordered and broken, therefore only 360 and 352 amino acid 
residues could be fitted, respectively. Chain A forms a dimer with chain B both in the same 
aymmetric unit, while chain C forms a dimer with chain C' in the adjacent crystal asymmetric 
unit. Illustrations of the three refined molecules in an asymmetric unit and the dimeric form 
(chains A and B) of L. lactis prolidase are in Figure 5.8 and Figure 5.9, respectively. 
 
 
 
Figure 5.6 Ball and stick model of the metal center in the structure of L. lactis prolidase 
showing the additional positive electron density. Electron density (2Fo-Fc) was contoured at 
6.62 rmsd. 
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Figure 5.7 X-ray fluorescence of recombinant wild type L. lactis prolidase crystal showing a 
strong signal for arsenic. 
The crystal was grown in a reservoir solution containing 0.16 M calcium acetate, 0.08 M sodium 
cacodylate (pH 6.5), 14 % PEG 8000 and 18 % glycerol. 
 
Each chain/ subunit of L. lactis prolidase has an N-terminal domain and a C-terminal 
domain made up of residues 1-124 and 133 - 362, respectively. The two domains are linked by a 
helical linker made up of residues 125 - 132 (Figure 5.10). The C-terminal domain harbours the 
enzyme active site, which comprises the two manganese atoms coordinated by five amino acid 
residues. The first manganese is coordinated by both oxygen atoms of the carboxylic group of 
Asp 221 (O
δ1
 and O
δ2
), O
ε1
 of Glu 339, and O
δ1
 of Asp 232. The second manganese atom is 
coordinated by O
δ2 
of Asp 232, O
ε2
 of Glu 325, O
ε2
 of Glu 339, and N
 ε2
 of His 296. The two 
manganese atoms are also coordinated by O
1
 of the cacodylate ion found in the metal center. 
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Figure 5.8 Cartoon representation of the three molecules of L. lactis prolidase. 
Chains A, B and C are coloured red, green and blue; respectively. The purple balls buried in the 
structure are manganese atoms. The pictures were drawn by Chimera (Pettersen et al., 2004). 
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Figure 5.9 Stereodiagrams of the dimer of L. lactis prolidase. 
Subunits A and B are coloured red and green, respectively. 
 
Located over the active site of each subunit is a loop structure from the other subunit, 
which is the loop shown to influence enzyme activity and its unique properties, such as allosteric 
behaviour (Zhang et al., 2009 and Yang & Tanaka 2008). The loop comprises twelve amino acid 
residues: Gly 32, Leu 33, Ala 34, Ile 35, Asp 36, Pro 37, His 38, Glu 39, Arg 40, Ile 41, Ala 42 
and Gly 43 (Figure 5.11). Among the 13 loop residues, Glu 39 of one subunit is the closest to the 
active site of the other subunit. The distances from the alpha carbon of Glu 39 in subunit A to the 
two manganese atoms in the active site of subunit B are 14.7 Å and 16.11 Å. The distances from 
the alpha carbon of Glu 39 in subunit B to the two manganese atoms in the active site of subunit 
A are 16.51 Å and 18.21 Å (Figure 5.12). 
 48 
 
 
 
Figure 5.10 A monomeric representation of wild-type L. lactis prolidase with the enzyme 
active site highlighted. 
A: The active site (metal center) is circled. The two domains are connected by a helical linker 
(residues 125 - 132). B: The five manganese-coordinating residues and the manganese atoms are 
shown, the latter are the purple balls. The coordination bonds are indicated by dashed lines. Not 
shown in this diagram is the cacodylate molecule, of which one of the oxygen atoms coordinates 
both the manganese atoms.  
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Figure 5.11 Structure of L. lactis prolidase showing the loop structure (residues 32 - 43) of 
one subunit over the active site of the other subunit. 
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Figure 5.12 Illustration of the distance from the alpha carbon on Glu 39 located in the loop 
of one subunit to the manganese atoms located in the active site of the other subunit of L. 
lactis prolidase. 
5.4 Structure quality 
Most of the quality parameters of the refined model indicate that the quality is acceptable 
(Table 5.3). For example, the difference between Rwork and Rfree (22.39 and 27.77) is about 5 %. 
The difference in R-factors for a well-refined structure is expected to be between 4 % and 7 %. 
When the Rwork is more than 7 % lower than the Rfree value it indicates possible over-
interpretation of the diffraction data, whereas a difference of these values smaller than 4 % may 
indicate that the Rfree reflections were used during refinement leading to model bias (Wlodawer et 
al., 2008). About 90 % of the modeled residues are in the favoured region of the Ramachandran 
plot, while 7.4 % and 2.6 % are in the allowed and disallowed regions, respectively. Of the 2.6 % 
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in the disallowed regions 80 % are in chain C, while the remaining 20 % are in chains A and B 
(Figure 5.13).  
 
Table 5.3 Refinement statistics of wild-type L. lactis prolidase. 
Space group  C 1 2 1 
Unit-cell parameters (Å, º) a = 212.13, b = 76.99 c = 88.92, α = γ = 90,  
β = 112.39 
Resolution range (Å) 49.83 - 2.25 (2.33  - 2.25) 
{I/σ (I)} 9.48 (1.74) 
Completeness (%) 99.94 (99.90) 
Total reflections 23,5259 (23,993) 
Unique reflections 63,058 (6,269) 
Multiplicity 3.7 (3.8) 
R merge  0.084 (0.80) 
Wilson B factor (Å
2
) 48.50 
R work /R free (%) 22.39/ 27.77 (31.25/ 32.48) 
No. of atoms 8646 
Protein 8302 
Ligands 27 
Water 317 
Mean B factor (Å
2
) 62.60 
R.m.s.d., bond lengths (Å) 0.023 
R.m.s.d., bond angles (º) 1.73 
Ramachandran favoured (%) 90 
Ramachandran allowed (%) 7.4 
Ramachandran outliers (%) 2.6 
Statistics for the highest-resolution shell are shown in parentheses 
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Figure 5.13 Ramachandran outliers in the refined model of L. lactis prolidase. 
 
In addition to Ramachandran outliers, some residues fit poorly to the electron density. 
However, most of them are located in chain C. Sixty three residues fit poorly to the electron 
density, 55 of which are located in chain C. This is not surprising, since molecule C has the least 
defined electron density of all the three molecules in the crystal asymmetric unit. It is important 
to note that the electron density map for the loop structures (residues 32 - 43) of subunits A and B 
are also complete and well-defined, thus the residues in this region fit the map well (Figure 5.14). 
Comparison of the structure of L. lactis prolidase with structures solved at similar resolution 
revealed that most of its quality parameters are within the expected ranges (Table 5.4).  
 
 53 
 
 
Figure 5.14 Electron density map (2Fo-Fc) of the loop structure (residues 32 - 43) of L. lactis 
prolidase at sigma level 1 rmsd. 
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Table 5.4 Comparison of the refinement statistics of the current structure with the range 
for structures solved at similar resolution. 
 Range of other structures
a
  Statistic for the current 
structure 
Rwork 13.83 - 24.96 22.39 
Rfree 16.42 - 32.42 27.77 
RMSD (bonds) 0.002 - 0.030 0.023 
RMSD (angles) 0.42 - 2.05 1.73 
Average B-factor 7.0 - 56.7 62.60 
a
The range is for 708 PDB structures solved at similar resolution (Urzhumtseva et al., 2009).  
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6 DISCUSSION 
6.1 Crystallization 
Successful growth of large three-dimensional crystals was achieved using both the hanging 
drop vapour diffusion and the microbatch-under-oil crystallization methods. The buffer, the 
precipitant and the ligand used were the same for both methods. This suggests that the chemical 
composition of the crystallization solution is more important than the crystallization method, at 
least in this study, in determining the success of a crystallization experiment. Manual screening 
of 96 commercial reagents identified several conditions, some of which grew X-ray-diffracting 
crystals upon optimization. Initially, bipyramidal-shaped crystals were grown, which tended to 
grow as twinned crystals rather than individual crystals. This compromised the quality of the 
diffraction data collected from these crystals. The crystals belonged to space group P1 and there 
was an estimate of six monomers of L. lactis prolidase in the crystal asymmetric unit. The low 
symmetry, high number of molecules in the crystal asymmetric unit, twinning and other errors in 
the crystal lowered the chance of solving the phase problem. Structure determination with this 
diffraction data was therefore, not successful. On the other hand, the high-throughput screening 
of 1536 conditions led to the identification of a diverse range of conditions that yielded crystals 
of different forms. Optimization of one of the lead conditions yielded crystals with a hexagonal 
shape. These crystals belonged to space group C2 with an estimate of three monomers in the 
crystal asymmetric unit. A smaller number of molecules in the crystal asymmetric unit and a 
higher symmetry of the crystal both make it suitable to solve the structure by X-ray 
crystallography. The shape of the crystal is determined by the internal arrangement of molecules 
in the crystal lattice, and the more symmetrical the internal arrangement the higher the number of 
equivalent reflections that can be collected with minimum radiation exposure. Thus, the more 
accurate the diffraction data from the higher symmetry crystals compared to the diffraction data 
from lower symmetry crystals. The conditions that produced the crystals from the two screening 
methods were very similar in the sense that they both comprised sodium cacodylate buffer (pH 
6.5), a divalent metal salt (calcium or manganese salt) and PEG 8000 as the precipitant. The 
crystallization condition from high-throughput screening contained glycerol in addition to these 
three other components. This shows that not only is the choice of the chemical composition of the 
crystallization solution important in determining the success of a crystallization experiment, but 
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also in determining the quality of the crystals grown and thus, the success of structure 
determination by X-ray crystallography. 
Co-crystallization of enzymes with their substrates, co-factors and other ligands has been 
reported to yield better crystallization results than crystallization of the enzyme alone. The co-
crystallants stabilize the enzyme and the stable form tends to crystallize better than the free, non-
stable form (McPherson, 2004). In this study, L. lactis prolidase was co-crystallized with its 
hydrolytic products, amino acids. Although this yielded three-dimensional crystals, preliminary 
analysis of diffraction data from one of the crystals suggested that the crystals were not of 
sufficient quality to collect a complete data set. However, this was not thoroughly investigated. 
Further experimentation would have to be performed, such as examining more crystals and 
different concentrations of the co-crystallants, before attempting to come up with a plausible 
explanation. 
In previous studies in Dr. Tanaka's research group, computer-generated models of L. lactis 
prolidase have proposed that this enzyme has a loop structure from one subunit close to the active 
site of the other subunit. Deletion of five amino acid residues from the loop, residues 36 - 40, led 
to loss of activity. However, the physical properties of this enzyme, including its dimeric nature, 
were preserved (Zhang et al., 2009). Therefore, it was speculated that the crystal structure of Δ36 
- 40 could still be used to elucidate the functional properties of L. lactis prolidase. Since the loop 
structure is flexible and crystallization involves packing of molecules in an ordered manner, it 
was hypothesized that Δ36 - 40 would have a higher success rate of crystallization than its wild-
type counterpart. The same conditions that crystallized wild-type prolidase also crystallized Δ36 - 
40. Surprisingly, crystals of Δ36 - 40 were not durable and did not diffract to high enough 
resolution for structure solution. The structural changes responsible for loss of activity in Δ36 - 
40 could be responsible for loss of molecular order during crystallization of Δ36 - 40 and 
compromised diffraction quality in crystals of Δ36 - 40. It is speculated that different conditions 
are required to form good quality crystals of Δ36 - 40 mutant prolidase. 
6.2 Model building and refinement 
The crystal structure of wild-type L. lactis prolidase was successfully solved and refined at 
2.25 Å resolution. The crystal asymmetric unit contained three molecules (chains A, B and C). 
The electron density of chain C was less ordered than the electron densities of chains A and B. 
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This explains why 90 % of the residues that fit poorly to the electron density are in chain C. Also, 
80 % of the residues in the disallowed region of the Ramachandran plot are in chain C. Among 
all the refinement parameters investigated, the average B-factors were the only ones that fell out 
of the expected range based on PDB structures solved at similar resolution. The range of 
structures solved at similar resolution is 7.0 - 56.7 Å
2
, whereas the average B-factor for the 
current model is 62.60 Å
2
 (Table 5.3). This could be due to the high disorder and incompleteness 
of chain C. It is not uncommon to find one of the molecules in the crystal asymmetric unit 
disordered and incomplete. This is the case with the structure of P. furiosus prolidase (1pv9), of 
which the asymmetric unit contains two molecules (Maher et al., 2004). Chain A of this structure 
contains 337 of the 348 residues and only four of them fit poorly to the electron density. Chain B, 
on the other hand, has only 318 residues fitted to the electron density due to its incompleteness 
and 30 of these residues fit poorly to the electron density. This represents 90 % of the residues 
that fit poorly to the electron density of the refined model. The structure of P. furiosus prolidase 
is, therefore, described using only chain A, half of the dimer (Maher et al., 2004). L. lactis 
prolidase also exists as a dimer biologically (Yang & Tanaka, 2008). Unlike P. furiosus prolidase 
model, the two molecules that are more ordered (chains A and B) form a dimer with each other. 
This indicates that the structural interpretation of this enzyme (a homodimeric model consisting 
of chain A and B) is not compromised by the low quality of chain C. 
6.3 Structure comparison with related proteins 
Previous research has revealed that L. lactis prolidase, unlike other prolidases, shows 
allosteric behaviour, metal-dependent substrate specificity and substrate inhibition (Yang & 
Tanaka, 2008). Comparison of the sequence-based computer-generated model of L. lactis 
prolidase with the crystal structure of P. furiosus prolidase reveals that there is a loop structure in 
both models. Interestingly, the loop in L. lactis prolidase is longer by four amino acid residues. 
This number coincides with the number of charged residues found in the middle of the loop 
structure in L. lactis prolidase (Asp 36, His 38, Glu 39 and Arg 40), which are not present in the 
loop of P. furiosus prolidase (Maher et al., 2004; Yang & Tanaka, 2008). This led to the 
hypothesis that the charged residues on the loop structure could be responsible for the unique 
features of L. lactis prolidase. The deletion of these residues leads to loss of activity of this 
enzyme (Zhang et al., 2009). Therefore, their roles in the catalytic properties of the enzyme 
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cannot be elucidated using the catalytically inactive mutant, Δ36 - 40. On the other hand, the 
inactivity of Δ36 - 40 suggests that the loop is involved in enzyme activity.  In the same study, 
they show that there is no evidence that the deletion of the loop residues (residues 36 - 40) 
influences the structural integrity of the dimer. The Δ36 - 40 mutant behaves similarly to the 
wild-type prolidase on gel filtration column. The loss of activity and little influence on the 
enzyme structure indicate that these loop residues are essential for activity, while their structural 
contribution to rigidity of the enzyme is minimum.  
In this crystallographic study, it has been confirmed that the loop structure of L. lactis 
prolidase is longer than the loop structure of P. furiosus prolidase. However, it is three amino 
acids longer, which is different from the previously reported four residues. This is also the case 
with another homologous structure, P. horikoshii prolidase (1wy2), whose loop structure is three 
amino acids shorter than the loop structure of L. lactis prolidase. The residues in the loop of L. 
lactis prolidase in positions equivalent to gaps in these homologous structures are His 38, Glu 39 
and Arg 40 (Figure 6.1). Two other homologous structures, prolidase from Thermococcus 
sibricus (4fkc) and a dipeptidase from P. horikoshii (2how), have loop structures the same length 
as the loop structure found in L. lactis prolidase (Figure 6.2). Glu 39 and Arg 40 (L. lactis 
prolidase numbering) are conserved among the structures with same length loop structure, while 
His 38 is not. Also structural comparisons revealed that Asp 36 is unique to L. lactis prolidase. 
Therefore, Asp 36 and His 38 are unique to L. lactis prolidase. This is summarized in Table 6.1. 
Previous mutation studies of these residues showed their importance in catalytic activity. 
Mutations of individual residues revealed that Asp 36 and His 38 are involved in allosteric 
behaviour and subtration inhibition, respectively. Glu 39 and Arg 40 were shown to be needed 
for catalytic activity (Zhang et al., 2011 and Chen & Tanaka, 2011). Allosteric behaviour, 
substrate inhibition and metal dependent substrate specificity have not been reported in any 
prolidase, including the ones with the same loop length as L. lactis prolidase. Therefore, this 
study supports the previously proposed involvement of Asp 36 and His 38 in allosteric behaviour 
and substrate inhibition of L. lactis prolidase, respectively. 
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Figure 6.1 Superposition of L. lactis prolidase with A: P. horikoshii OT3 prolidase (1wy2) 
and B: P. furiosus prolidase (1pv9). 
L. lactis prolidase is coloured green while P. horikoshii and P. furiosus prolidase structures are 
coloured red. The amino acid numbering is for L. lactis prolidase. His 38, Glu 39 and Arg 40 are 
found in L. lactis prolidase, but not in P. horikoshii and P. furiosus prolidase structures. 
Superposition of the structures was done using Jmol (Holm & Rosenström, 2010). 
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Figure 6.2 Superposition of L. lactis prolidase with A: T. sibricus prolidase (4fkc) and B: 
putative dipeptidase from P. horikoshii (2how). 
L. lactis prolidase is coloured green while T. sibricus prolidase and P. horikoshii putative 
dipeptidase structures are coloured red. The amino acid numbering is for L. lactis prolidase. The 
residues in T. sibricus prolidase positions equivalent to His 38, Glu 39 and Arg 40 of L. lactis 
prolidase are Leu, Glu and Arg. and the residues in P. horikoshii putative dipeptidase positions 
equivalent to His 38, Glu 39 and Arg 40 of L. lactis prolidase are Gly, Glu and Arg. 
Superposition of the structures was done using Jmol (Holm & Rosenström, 2010). 
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Table 6.1 A summary of the comparison of the loop structures of L. lactis prolidase and 
related proteins. 
 Residue number* and identification 
Structure 32 33 34 35 36 37 38 39 40 41 42 43 
L. lactis prolidase G L A I D P H E R I A G 
P. furiosus prolidase G T S P L G - - - G G Y 
P. horikoshii prolidase G A S P L A - - - G G Y 
T. sibricus prolidase G F N P L T L E R L F V 
P. horikoshii dipeptidase G L R L H V G E R L A I 
*The numbering is for L. lactis prolidase. 
"-" indicates that there is a gap (no amino acid residue) in the equivalent position of a 
homologous protein. 
 
In addition to Asp 36 and His 38 not being conserved among these prolidases, Arg 293, 
mutation of which does not show allosteric behaviour (Zhang et al., 2009), is not conserved in 
prolidases from P. furiosus and P. horikoshii. The residue in position equivalent to Arg 293 in 
these two structures is serine. Therefore, not only do these homologous structures lack the 
charged residues in their loop structures, but they also lack the charged arginine residue proximal 
to the active site of L. lactis prolidase. Comparison of the metal centers of these related enzymes 
revealed that their metal-coordinating amino acid residues are not only conserved, but also have 
almost identical coordination relative to their metal cations (Figure 6.3). Therefore, these residues 
are not likely to be responsible for the unique catalytic features of L. lactis prolidase. It should be 
noted that of the four related proteins that were compared with L. lactis prolidase, two are 
illustrated in Figure 6.3. These were judiciously chosen to represent both categories of the loop 
structure size, shorter loop structure and loop structure of the same length as that of L. lactis 
prolidase. The metal centers and metal coordination of the other structures are similar to the ones 
illustrated in Figure 6.3.  
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Figure 6.3 Illustration of the metal-coordinating residues of L. lactis prolidase and 
homologous structures. A: L. lactis prolidase, B: T. sibricus prolidase and C: P. furiosus 
prolidase. 
Manganese, cadmium and zinc found in the metal centers of L. lactis prolidase, T. sibricus 
prolidase and P. furiosus prolidase structures are coloured purple, blue and orange, respectively. 
 
The loop structure is more flexible than other secondary structures found in proteins, such 
as β sheets and α helices. In addition to its flexibility, located at both ends of the loop structure of 
L. lactis prolidase are glycine residues (Figure 5.14). Due to its size, it exhibits the least steric 
hindrance among the 20 standard amino acids and gives the structures it is found in flexibility. 
Therefore, the two glycine residues found at both ends of the loop structure of L. lactis prolidase 
may act as hinges that allow the movement of the loop. We propose that upon substrate binding, 
the two subunits of L. lactis prolidase move closer to each other (Figure 6.4) and the loop 
residues (including Asp 36 and His 38) and the residues proximal to the active site (e.g. Arg 293) 
bind. These intersubunit interactions affect the binding of further substrate molecules and leads to 
demonstration of allostery. Substrate-induced intersubunit interactions responsible for allosteric 
behaviour have been reported in other enzymes, such as Escherichia coli phoshofructokinase-2 
(Cabrera et al., 2008; Caniuguir et al., 2005). 
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Figure 6.4 Stereodiagrams showing the proximity of the active site and the loop residues of 
L. lactis prolidase. A: The loop structure is closer to the active site and B: The loop 
structure is further from the active site.  
The loop structure is shown with a cyan ribbon and manganese atoms are shown in Van der 
Waals model (red).   
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6.4 Proposed mechanism of L. lactis prolidase catalysis 
It has been shown that a mutation of His 303 does not show enzyme activity (Zhang et al., 
2009). Structural comparison in this current study shows that this amino acid residue is conserved 
among prolidases. This residue is located near the metal cluster, but is not involved in metal 
coordination (Figure 5.10). These findings suggest that His 303 may be involved in this enzyme's 
function. The mechanism of prolidase catalysis has been been previously proposed (Alberto et 
al., 2011). The proposed mechanism involves the transfer of a proton from a hydroxide ion to the 
nitrogen of proline found in the proline dipeptide (substrate) by one of the two glutamic acids 
coordinating one of the two metal atoms. This leads to the liberation of proline and the other 
amino acid from the dipeptide (Alberto et al., 2011). In this study, we propose that His 303 is 
involved in the initial steps of peptide hydrolysis by L. lactis prolidase. Prolidase from L. lactis 
and other microorganisms demonstrate optimum activity at pH 7.0 or higher (Ghosh et al., 1998; 
Theriot et al., 2010; Wang et al., 2005; Yang & Tanaka, 2008). This pH is higher than the pKa 
value of approximately 6.0 for the side chain of histidine. Therefore, its imidazole ring is 
unprotonated and nucleophilic at prolidase optimum pH. We propose that the nucleophilic 
imidazole nitrogen of His 303 abstracts a proton from a surrounding water molecule leading to 
the production of a nucleophilic hydroxide ion. The hydroxide ion then attacks the carbonyl 
carbon of the peptide bond and the rest of the reaction proceeds as previously proposed (Alberto 
et al., 2011). The proposed mechanism of catalysis of L. lactis prolidase is illustrated in Figure 
6.5. Glutamic acid responsible for proton transfer in the proposed mechanism of catalysis of L. 
lactis prolidase is Glu 325 using its carboxylic oxygen, O
ε1
. This is the only oxygen atom free 
from metal coordination among the oxygen atoms of the two glutamates and the two aspartates 
coordinating the two manganese atoms (Figure 6.3).  
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Figure 6.5 The proposed mechanism of dipeptide hydrolysis by L. lactis prolidase. 
His 303 imidazole nitrogen abstracts a proton from a water molecule making it nucleophilic. The 
resulting hydroxide ion then attacks the carbonyl carbon of a proline dipeptide bond. Glu 325 
then abstracts a hydrogen atom from the hydroxyl group bonded to the carbonyl carbon of the 
dipeptide and transfers it to proline nitrogen. This leads to the liberation of free proline and the 
other amino acid (Xaa) of the dipeptide. 
 
Prolidases from P. furiosus and P. horikoshii prefer cobalt over manganese for catalytic 
activity (Maher et al., 2004; Theriot et al., 2010); whereas L. lactis prolidase shows activities 
with zinc and manganese. Interestingly, L. lactis prolidase shows the highest activity with zinc 
when the subtrate is Leu - Pro, but when the substrate is Arg - Pro the highest catalytic rate is 
shown with manganese (Yang & Tanaka , 2008).  Altogether, these findings show that not only is 
the presence of metal atoms in the enzyme active site important for its activity, but also is the 
identity of the metal involved. Mutations targeted at amino acid residues binding one or both of 
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the metals in the structure of P. furious prolidase led to reduced or lost enzyme activity (Du et al., 
2005). This further supports the significance of metals in prolidase activity, but their direct 
contribution has never been elucidated. In the proposed mechanism of catalysis of prolidase, one 
of the residues coordinating the metal center (Glu 325 of L. lactis prolidase) is also directly 
involved in enzyme catalysis. The role of metal atoms in prolidase catalysis could, therefore, be 
the positioning of the active site residues and the substrate so that they can effectively transfer 
protons/ electrons between them for hydrolysis. In this study, metal-dependent substrate 
specificity was not clearly explained. The metal-dependent substrate specificity of L. lactis 
prolidase could be due to the fact that different metal atoms have different sizes, therefore, when 
present in the active site would position the active site residues differently leading to different 
binding affinities of subtrates. This would lead to different catalytic properties. It would possibly 
require comparison of the current structure with a structure complex with zinc in the active site to 
reveal what structural differences exist in the presence of different metal atoms in the metal 
cluster. 
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7 SUMMARY AND CONCLUSIONS 
The structure of proline is unique among the standard amino acids. Due to this uniqueness, 
proline-containing peptides are less susceptible to hydrolysis by general peptidases than other 
peptides. Proline-specific peptidases play a critical role in liberating proline and other amino 
acids in proline peptides for various functions. These peptidases are involved in hydrolysis of 
milk caseins by LAB, which rely on the proteolytic system for their amino acid requirements. 
Hydrolysis of hydrophobic peptides in fermented dairy products, including cheeses, has been 
shown to reduce their bitterness. Collagen, which is the most abundant protein in humans, is rich 
in proline. Therefore, proline-specific peptidases are involved in its catabolism for proline 
recycling and protein synthesis. Two proline-specific dipeptidases (prolinase and prolidase) are 
involved in the final breakdown of proline-rich peptides. They hydrolyze dipeptides with proline 
in the N- and C-terminal ends of the peptides, respectively. Lack of prolidase activity has been 
associated with a hereditary disorder known as prolidase deficiency. Prolidase has been also 
shown to have structural and functional similarities with organophosphorus acid anhydrolase 
(OPAA), including shared substrates among the two groups of enzymes. These facts suggest that 
L. lactis prolidase could potentially be used in debittering of fermented dairy products, in treating 
prolidase deficiency and in toxic organophosphorus compounds  detoxification.  
L. lactis prolidase has been previously characterized and its catalytic properties elucidated. 
Unlike other prolidases, it demonstrates allosteric behaviour, metal-dependent substrate 
specificity and substrate inhibition. The current study focused on the three-dimensional structure 
determination of L. lactis prolidase by X-ray crystallography. Hexagonal plate-like crystals were 
grown to about 50 µm in their longest dimension using the hanging drop vapour diffusion 
method. The crystals yielded medium resolution data and successful structure determination was 
done using molecular replacement method. Three molecules were located in the asymmetric unit 
of the crystal and the structure was refined against 2.25 Å resolution data. Molecule A and 
molecule B form a dimer with each other, while molecule C forms a dimer with another molecule 
in the adjacent crystal asymmetric unit. Molecule C is disordered and incomplete, while 
molecules A and B are well defined. Although this compromises the quality of the refined model, 
it does not compromise its structural interpretation since L. lactis exits as a dimer biologically 
and the dimer-forming subunits in the asymmetric unit are well defined.  
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Each subunit of L. lactis prolidase has a C- and N-terminal domains linked by a helical 
linker. The enzyme active site is located in the C-terminal domain and comprises two manganese 
atoms coordinated by five amino acid residues: two aspartates, two glutamates and histidine. The 
crystal structure of L. lactis has a loop structure from one subunit over the active site of the other 
subunit. Comparison with prolidases from P. horikoshii (1wy2) and P. furiosus (1pv9) reveals 
that L. lactis prolidase loop is longer by three amino acid residues: His 38, Glu 39 and Arg 40. 
On the other hand, the loop is the same length as the loops in other two homologous structures, P. 
horikoshii putative dipeptidase (2how) and T. sibricus prolidase (4fkc). Glu 39 and Arg 40 are 
conserved among the structures of the same length while His 38 is not. Also, Asp 36 on the loop 
is unique to L. lactis prolidase. Previously, site-directed mutagenesis studies have suggested that 
it is the charge-charge interaction between Asp 36 of one subunit and Arg 293 of the other 
subunit that is responsible for the allosteric behaviour of this enzyme. His 38 was suggested to be 
involved in substrate inhibition. The fact that the crystal structure reveals that these two loop 
amino acids (Asp 36 and His 38) are unique to L. lactis further supports their previously 
proposed involvement in these unique catalytic properties of this prolidase. His 303, of which 
mutation does not show enzymatic activity, is conserved among the prolidases investigated. The 
crystal structure shows this amino acid residue is located near the enzyme active site, but it is not 
involved in metal coordination. We propose that this amino acid acts as a nucleophile to initiate 
the hydrolysis of peptide substrates by L. lactis prolidase. The role of metals in the active site of 
prolidases, including L. lactis prolidase, could be the effective positioning of active site residues 
for substrate hydrolysis.  
Through the crystal structure analysis combined with previously reported kinetic 
information, this research successfully indicated that the putative loop structure exists as 
predicted. The location of the loop and the identity of the residues on it support its involvement in 
the unique catalytic properties of L. lactis prolidase including allosteric behaviour and substrate 
inhibition. Metal dependent substrate specificity, on the other hand, could not be explained with 
the current data. Further crystallographic studies are required to help explain this unique property 
of L. lactis prolidase. 
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8 RECOMMENDATIONS FOR FUTURE WORK 
Future studies should include X-ray crystallography of various mutants of L. lactis 
prolidase that have been previously characterized. Comparison of the structures of these mutants 
with that of the wild-type will reveal the structural changes that may be responsible for their 
different kinetic properties. Co-crystallization experiments should also be conducted. The co-
crystallants should include substrate analogues and different metal ions. The structure with the 
substrate analogues bound to its active site will reveal the interactions of the substrate and the 
active site residues (local interaction) as well as any global conformations that may result from 
substrate binding. As stated earlier, one of the unique properties of L. lactis prolidase is its metal 
dependent-substrate specificity. Therefore, crystal structures with different metal ions should help 
elucidate the contribution of these metal ions in the enzyme catalysis. All this information shall 
be valuable in the potential application of L. lactis prolidase in cheese debittering, treatment of 
prolidase deficiency and detoxification of organophosphorus compounds. 
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10  APPENDIX 
Table A1. Hampton Research Crystal Screen HR2-110 reagent formulation. 
Reagent 
# 
Formulation 
1 30 % v/v 2-Methyl-2, 4-pentanedio, 0.1 M Sodium acetate trihydtrate pH 4.6, 0.02 M 
Calcium chloride dihydrate 
2 0.4 M Potassium sodium tartrate tetrahydrate  
3 0.4 M Ammonium phosphate monobasic 
4 2.0 M Ammonium sulfate, 0.1 M TRIS hydrochloride pH 8.5 
5 30 % v/v 2-Methyl-2, 4-pentanediol, 0.1 M HEPES sodium pH 7.5, 0.2 M Sodium 
citrate tribasic dihydrate  
6 30 % w/v Polyethylene glycol 4,000, 0.1 M TRIS hydrochloride pH 8.5, 0.2 M, 
Magnesium chloride hexahydrate 
7 1.4 M Sodium acetate trihydrate, 0.1 M Sodium cacodylate trihydrate pH 6.5 
8 30 % v/v 2-Propanol, 0.1 M Sodium cacodylate trihydrate pH 6.5, 0.2 M Sodium 
citrate tribasic dihydrate 
9 30 % w/v Polyethylene glycol 4,000, 0.1 M Sodium citrate tribasic dihydrate pH 5.6, 
0.2 M Ammonium acetate 
10 30 % w/v Polyethylene glycol 4,000, 0.1 M Sodium acetate trihydrate pH 4.6, 0.2 M 
Ammonium acetate 
 11 1.0 M Ammonium phosphate monobasic, 0.1 M Sodium citrate tribasic dihydrate pH 
5.6 
12 30 % v/v 2-Propanol, 0.1 M HEPES sodium pH 7.5, 0.2 M Magnesium chloride 
hexahydrate 
13 30% v/v Polyethylene glycol 400, 0.1 M TRIS hydrochloride pH 8.5, 0.2 M Sodium 
citrate tribasic dihydrate 
14 28 % v/v Polyethylene glycol 400, 0.1 M HEPES sodium pH 7.5, 0.2 M Calcium 
chloride dihydrate 
15 30 % w/v Polyethylene glycol 8,000, 0.1 M Sodium cacodylate trihydrate pH 6.5, 0.2 
M Ammonium sulfate 
16 1.5 M Lithium sulfate monohydrate, 0.1 M HEPES sodium pH 7.5 
17 30 % w/v Polyethylene glycol 4,000, 0.1 M TRIS hydrochloride pH 8.5, 0.2 M 
Lithium sulfate monohydrate 
18 20 % w/v Polyethylene glycol 8,000, 0.1 M Sodium cacodylate trihydrate pH 6.5, 0.2 
M Magnesium acetate tetrahydrate 
19 30 % v/v 2-Propanol, 0.1 M TRIS hydrochloride pH 8.5, 0.2 M Ammonium acetate 
20 25 % w/v Polyethylene glycol 4,000, 0.1 M Sodium acetate trihydrate pH 4.6, 0.2 M 
Ammonium sulfate 
21 30 % v/v (+/-)-2-Methyl-2, 4-pentanediol, 0.1 M Sodium cacodylate trihydrate pH 6.5 
22 30 % w/v Polyethylene glycol 4,000, 0.1 M TRIS hydrochloride pH 8.5, 0.2 M 
Sodium acetate trihydrate 
23 30 % v/v Polyethylene glycol 400, 0.1 M HEPES sodium pH 7.5, 0.2 M Magnesium 
chloride hexahydrate 
24 20 % v/v 2-Propanol, 0.1 M Sodium acetate trihydrate pH 4.6, 0.2 M Calcium 
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chloride dihydrate 
25
#
 1.0 M Sodium acetate trihydrate, 0.1 M Imidazole pH 6.5 
26 30 % v/v (+/-)-2-Methyl-2, 4-pentanediol, 0.1 M Sodium citrate tribasic dihydrate pH 
5.6, 0.2 M Ammonium acetate 
27
#
 20% v/v 2-Propanol, 0.1 M HEPES sodium pH 7.5, 0.2 M Sodium citrate tribasic 
dihydrate 
28 30 % w/v Polyethylene glycol 8,000, 0.1 M Sodium cacodylate trihydrate pH 6.5, 0.2 
M Sodium acetate trihydrate 
29 0.8 M Potassium sodium tartrate tetrahydrate, 0.1 M HEPES sodium pH 7.5 
30 30 % w/v Polyethylene glycol 8,000, 0.2 M Ammonium sulfate 
31 30 % w/v Polyethylene glycol 4,000, 0.2 M Ammonium sulfate 
32 2.0 M Ammonium sulfate 
33 4.0 M Sodium formate 
34 2.0 M Sodium formate, 0.1 M Sodium acetate trihydrate pH 4.6 
35 0.8 M Sodium phosphate monobasic monohydrate, 0.8 M Potassium phosphate 
monobasic, 0.1 M HEPES sodium pH 7.5 
36 8 % w/v Polyethylene glycol 8,000, 0.1 M TRIS hydrochloride pH 8.5 
37 8 % w/v Polyethylene glycol 4,000, 0.1 M Sodium acetate trihydrate pH 4.6 
38 1.4 M Sodium citrate tribasic dihydrate, 0.1 M HEPES sodium pH 7.5 
39 2 % v/v Polyethylene glycol 400, 2.0 M Ammonium sulfate, 0.1 M HEPES sodium 
pH 7.5 
40 20 % v/v 2-Propanol, 20 % w/v Polyethylene glycol 4,000, 0.1 M Sodium citrate 
tribasic dihydrate pH 5.6 
41 10 % v/v 2-Propanol, 20 % w/v Polyethylene glycol 4,000, 0.1 M HEPES sodium pH 
7.5 
42 20 % w/v Polyethylene glycol 8,000, 0.05 M Potassium phosphate monobasic 
43 30 % w/v Polyethylene glycol 1,500 
44 0.2 M Magnesium formate dihydrate 
45 18 % w/v Polyethylene glycol 8,000, 0.1 M Sodium cacodylate trihydrate pH 6.5, 0.2 
M Zinc acetate dihydrate 
46 18 % w/v Polyethylene glycol 8,000, 0.1 M Sodium cacodylate trihydrate pH 6.5, 0.2 
M Calcium acetate hydrate 
47 2.0 M Ammonium sulfate, 0.1 M Sodium acetate trihydrate pH 4.6 
48 2.0 M Ammonium phosphate monobasic, 0.1 M TRIS hydrochloride pH 8.5 
49 2 % w/v Polyethylene glycol 8,000, 1.0 M Lithium sulfate monohydrate 
50 15 % w/v Polyethylene glycol 8,000, 0.5 M Lithium sulfate monohydrate 
#
Did not use this reagent for screening based on its poor record of producing crystals (Rowlett 
2005) 
 
Table A2. Hampton Research Crystal Screen 2 HR2-112 reagent formulation. 
Reagent 
# 
Formulation 
1 10 % w/v Polyethylene glycol 6,000, 2.0 M Sodium chloride  
2 0.01 M Hexadecyltrimethylammonium bromide, 0.5 M Sodium chloride, 0.01 M 
Magnesium chloride hexahydrate  
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3 25 % v/v Ethylene glycol 
4 35 % v/v 1,4-Dioxane 
5 5 % v/v 2-Propanol, 2.0 M Ammonium sulfate 
6 1.0 M Imidazole pH 7.0 
7 10 % w/v Polyethylene glycol 1,000, 10 % w/v Polyethylene glycol 8,000 
8 10 % v/v Ethanol, 1.5 M Sodium chloride 
9 2.0 M Sodium chloride, 0.1 M Sodium acetate trihydrate pH 4.6 
10 30 % v/v (+/-)-2-Methyl-2, 4-pentanediol, 0.1 M Sodium acetate trihydrate pH 4.6, 
0.2 M Sodium chloride 
 11 1.0 M 1,6-Hexanediol, 0.1 M Sodium acetate trihydrate pH 4.6, 0.01 M Cobalt (II) 
chloride hexahydrate 
12 30 % v/v Polyethylene glycol 400, 0.1 M Sodium acetate trihydrate pH 4.6, 0.1 M 
Cadmium chloride hydrate 
13 30 % w/v Polyethylene glycol monomethyl ether 2,000, 0.1 M Sodium acetate 
trihydrate pH 4.6, 0.2 M Ammonium sulfate 
14 2.0 M Ammonium sulfate, 0.1 M Sodium citrate tribasic dihydrate pH 5.6, 0.2 M 
Potassium sodium tartrate tetrahydrate 
15 1.0 M Lithium sulfate monohydrate, 0.1 M Sodium citrate tribasic dihydrate pH 5.6, 
0.5 M Ammonium sulfate 
16 2 % v/v Ethylene imine polymer, 0.1 M Sodium citrate tribasic dihydrate pH 5.6, 0.5 
M Sodium chloride 
17 35 % v/v tert-Butanol, 0.1 M Sodium citrate tribasic dihydrate pH 5.6 
18 10 % v/v Jeffamine M-600, 0.1 M Sodium citrate tribasic dihydrate pH 5.6, 0.01 M 
Iron (III) chloride hexahydrate 
19 2.5 M 1,6-Hexanediol, 0.1 M Sodium citrate tribasic dihydrate pH 5.6 
20 1.6 M Magnesium sulfate heptahydrate, 0.1 M MES monohydrate pH 6.5 
21 2.0 M Sodium chloride, 0.1 M MES monohydrate pH 6.5, 0.1 M Sodium phosphate 
monobasic monohydrate, 0.1 M Potassium phosphate monobasic 
22 12 % w/v Polyethylene glycol 20,000, 0.1 M MES monohydrate pH 6.5 
23 10 % v/v 1,4-Dioxane, 0.1 M MES monohydrate pH 6.5, 1.6 M Ammonium sulfate 
24 30 % v/v Jeffamine M-600 ®, 0.1 M MES monohydrate pH 6.5, 0.05 M Cesium 
chloride 
25 1.8 M Ammonium sulfate, 0.1 M MES monohydrate pH 6.5, 0.01 M Cobalt (II) 
chloride hexahydrate 
26 30 % w/v Polyethylene glycol monomethyl ether 5,000, 0.1 M MES monohydrate pH 
6.5, 0.2 M Ammonium sulfate 
27 25% v/v Polyethylene glycol monomethyl ether 550, 0.1 M MES monohydrate pH 
6.5, 0.01 M Zinc sulfate heptahydrate 
28 1.6 M Sodium citrate tribasic dihydrate pH 6.5 
29 30 % v/v (+/-)-2-Methyl-2, 4-pentanediol, 0.1 M HEPES pH 7.5, 0.5 M Ammonium 
sulfate 
30 10 % w/v Polyethylene glycol 6,000, 5 % v/v (+/-)-2-Methyl-2, 4-pentanediol, 0.1 M 
HEPES pH 7.5 
31 20% v/v Jeffamine M-600 ®, 0.1 M HEPES pH 7.5,  
32 1.6 M Ammonium sulfate, 0.1 M HEPES pH 7.5, 0.1 M Sodium chloride 
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33 2.0 M Ammonium formate, 0.1 M HEPES pH 7.5 
34 1.0 M Sodium acetate trihydrate, 0.1 M HEPES pH 7.5, 0.05 M Cadmium sulfate 
hydrate 
35 70 % v/v (+/-)-2-Methyl-2, 4-pentanediol, 0.1 M HEPES pH 7.5 
36 4.3 M Sodium chloride, 0.1 M HEPES pH 7.5 
37 10 % w/v Polyethylene glycol 8,000, 8 % v/v Ethylene glycol, 0.1 M HEPES pH 7.5 
38 20 % w/v Polyethylene glycol 10,000, 0.1 M HEPES pH 7.5 
39 3.4 M 1,6-Hexanediol, 0.1 M Tris pH 8.5, 0.2 M Magnesium chloride hexahydrate 
40 25 % v/v tert-Butanol, 0.1 M Tris pH 8.5 
41 1.0 M Lithium sulfate monohydrate, 0.1 M Tris pH 8.5, 0.01 M Nickel (II) chloride 
hexahydrate 
42 12 % v/v Glycerol, 0.1 M Tris pH 8.5, 1.5 M Ammonium sulfate 
43 50 % v/v (+/-)-2-Methyl-2, 4-pentanediol, 0.1 M Tris pH 8.5, 0.2 M Ammonium 
phosphate monobasic 
44 20 % v/v Ethanol, 0.1 M Tris pH 8.5 
45 20 % w/v Polyethylene glycol monomethyl ether 2,000, 0.1 M Tris pH 8.5, 0.01 M 
Nickel (II) chloride hexahydrate 
46 20 % v/v Polyethylene glycol monomethyl ether 550, 0.1 M BICINE pH 9.0, 0.1 M 
Sodium chloride 
47 2.0 M Magnesium chloride hexahydrate, 0.1 M BICINE pH 9.0 
48 2 % v/v 1,4-Dioxane, 10% w/v Polyethylene glycol 20,000, 0.1 M BICINE pH 9.0 
 
Table A3.  Self-made crystallization reagent formulations: Optimization of Hampton 
Research lead conditions.  
Reagent # Formulation 
1 10 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M Mg Acetate 
2 10 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M Ca Acetate 
3 10 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M ZnCl2 
4 10 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M MnCl2 
5 12 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M Mg Acetate 
6 12 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M Ca Acetate 
7 12 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M ZnCl2 
8 12 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M MnCl2 
9 14 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M Mg Acetate 
10 14 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M Ca Acetate 
11 14 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M ZnCl2 
12 14 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M MnCl2 
13 16 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M Mg Acetate 
14 16 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M Ca Acetate 
15 16 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M ZnCl2 
16 16 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M MnCl2 
17 18 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M Mg Acetate 
18 18 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M Ca Acetate 
19 18 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M ZnCl2 
20 18 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M MnCl2 
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21 20 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M Mg Acetate 
22 20 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M Ca Acetate 
23 20 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M ZnCl2 
24 20 % PEG 8000, 0.1 M Na Cacodylate (pH 6.0), 0.1 M MnCl2 
25 10 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Mg Acetate 
26 10 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Ca Acetate 
27 10 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M ZnCl2 
28 10 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
29 12 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Mg Acetate 
30 12 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Ca Acetate 
31 12 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M ZnCl2 
32 12 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
33 14 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Mg Acetate 
34 14 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Ca Acetate 
35 14 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M ZnCl2 
36 14 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
37 16 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Mg Acetate 
38 16 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Ca Acetate 
39 16 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M ZnCl2 
40 16 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
41 18 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Mg Acetate 
42 18 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Ca Acetate 
43 18 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M ZnCl2 
44 18 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
45 20 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Mg Acetate 
46 20 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Ca Acetate 
47 20 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M ZnCl2 
48 20 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
49 10 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M Mg Acetate 
50 10 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M Ca Acetate 
51 10 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M ZnCl2 
51 10 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M MnCl2 
53 12 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M Mg Acetate 
54 12 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M Ca Acetate 
55 12 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M ZnCl2 
56 12 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M MnCl2 
57 14 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M Mg Acetate 
58 14 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M Ca Acetate 
59 14 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M ZnCl2 
60 14 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M MnCl2 
61 16 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M Mg Acetate 
62 16 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M Ca Acetate 
63 16 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M ZnCl2 
64 16 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M MnCl2 
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65 18 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M Mg Acetate 
66 18 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M Ca Acetate 
67 18 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M ZnCl2 
68 18 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M MnCl2 
69 20 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M Mg Acetate 
70 20 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M Ca Acetate 
71 20 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M ZnCl2 
72 20 % PEG 8000, 0.1 M Na Cacodylate (pH 7.0), 0.1 M MnCl2 
73 11 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
74 12 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2  
75 13 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
76 14 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
77 15 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
78 16 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
79 11 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2, 10 mM Leu-Pro 
80 12 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2, 10 mM Leu-Pro 
81 13 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2, 10 mM Leu-Pro 
82 14 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2, 10 mM Leu-Pro 
83 15 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2, 10 mM Leu-Pro 
84 16 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2, 10 mM Leu-Pro 
85 14 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2, 5 mM Leu 
86 15 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2, 5 mM Leu 
87 16 % PEG 8000, 0.1 M Na Cacodylate (6.5), 0.1 M MnCl2, 5 mM Leu 
88 14 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2, 10 mM Leu 
89 15 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2, 10 mM Leu 
90 16 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2, 10 mM Leu 
91 15 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Ca Acetate, 5 mM Leu-Pro 
92 16 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Ca Acetate, 5 mM Leu-Pro 
93 17 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Ca Acetate, 5 mM Leu-Pro 
94 15 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Ca Acetate, 10 mM Leu-Pro 
95 16 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Ca Acetate, 10 mM Leu-Pro 
96 17 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Ca Acetate, 10 mM Leu-Pro 
97 11 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.2 M MnCl2 
98 12 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.2 M MnCl2 
99 13 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.2 M MnCl2 
100 14 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.2 M MnCl2 
101 15 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.2 M MnCl2 
102 16 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.2 M MnCl2 
103 11 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Ca Acetate 
104 12 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Ca Acetate 
105 13 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Ca Acetate 
106 14 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Ca Acetate 
107 15 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Ca Acetate 
108 16 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Ca Acetate 
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109 17 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Ca Acetate 
109 11 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Mg Acetate 
110 12 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Mg Acetate 
111 13 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Mg Acetate 
112 14 % PEG 8000, 0.1 M Na Cacodylate (6.5), 0.1 M Mg Acetate 
113 15 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Mg Acetate 
114 16 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Mg Acetate 
115 11 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Co (II) Nitrate 
116 12 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Co (II) Nitrate 
117 13 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Co (II) Nitrate 
118 14 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Co (II) Nitrate 
119 15 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Co (II) Nitrate 
120 16 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M Co (II) Nitrate 
121 11 % PEG 6000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
122 12 % PEG 6000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
123 13 % PEG 6000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
124 14 % PEG 6000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
125 15 % PEG 6000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
126 16 % PEG 6000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
127 17 % PEG 6000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
128 18 % PEG 6000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
129 19 % PEG 6000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
130 20 % PEG 6000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
131 21 % PEG 6000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
132 22 % PEG 6000, 0.1 M Na Cacodylate (pH 6.5), 0.1 M MnCl2 
133 11 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.2 M MnCl2 
134 12 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.2 M MnCl2  
135 13 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.2 M MnCl2 
136 14 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.2 M MnCl2 
137 15 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.2 M MnCl2 
138 16 % PEG 8000, 0.1 M Na Cacodylate (pH 6.5), 0.2 M MnCl2 
 
Table A4.  Self-made crystallization reagent formulations: Optimization of Hauptman 
Woodward Research Institute lead conditions 
1  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 11 
% (w/v) PEG 8000, 20 % (v/v) glycerol 
2  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 12 
% (w/v) PEG 8000, 20 % (v/v) glycerol 
3  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 13 
% (w/v) PEG 8000, 20 % (v/v) glycerol 
4  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 20 % (v/v) glycerol 
5  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 15 
% (w/v) PEG 8000, 20 % (v/v) glycerol 
6  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 16 
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% (w/v) PEG 8000, 20 % (v/v) glycerol 
7  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 17 % (v/v) glycerol 
8  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 18 % (v/v) glycerol 
9  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 19 % (v/v) glycerol 
10  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 20 % (v/v) glycerol 
11  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 21 % (v/v) glycerol 
12  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 22 % (v/v) glycerol 
13  0.2 M Calcium chloride (pH 6.5), 18 % (w/v) PEG 3350 
14  0.2 M Calcium chloride (pH 6.5), 19 % (w/v) PEG 3350 
15  0.2 M Calcium chloride (pH 6.5), 20 % (w/v) PEG 3350 
16  0.2 M Calcium chloride (pH 6.5), 21 % (w/v) PEG 3350 
17  0.2 M Calcium chloride (pH 6.5), 22 % (w/v) PEG 3350 
18  0.2 M Calcium chloride (pH 6.5), 23 % (w/v) PEG 3350 
19  0.2 M Calcium acetate  hydrate (pH 7.5), 18 % (w/v) PEG 3350 
20  0.2 M Calcium acetate  hydrate (pH 7.5), 19 % (w/v) PEG 3350 
21  0.2 M Calcium acetate  hydrate (pH 7.5), 20 % (w/v) PEG 3350 
22  0.2 M Calcium acetate  hydrate (pH 7.5), 21 % (w/v) PEG 3350 
23  0.2 M Calcium acetate  hydrate (pH 7.5), 22 % (w/v) PEG 3350 
24  0.2 M Calcium acetate  hydrate (pH 7.5), 23 % (w/v) PEG 3350 
25  0.1 M Lithium chloride, 0.1 M Tris (pH 8.0), 17 % PEG 8000 
26  0.1 M Lithium chloride, 0.1 M Tris (pH 8.0), 18 % PEG 8000 
27  0.1 M Lithium chloride, 0.1 M Tris (pH 8.0), 19 % PEG 8000 
28  0.1 M Lithium chloride, 0.1 M Tris (pH 8.0), 20 % PEG 8000 
29  0.1 M Lithium chloride, 0.1 M Tris (pH 8.0), 21 % PEG 8000 
30  0.1 M Lithium chloride, 0.1 M Tris (pH 8.0), 22 % PEG 8000 
31  0.1 M Ammonium thiocyanate, 0.1 M Tris (pH 8.0), 17 % PEG 8000 
32  0.1 M Ammonium thiocyanate, 0.1 M Tris (pH 8.0), 18 % PEG 8000 
33  0.1 M Ammonium thiocyanate, 0.1 M Tris (pH 8.0), 19 % PEG 8000 
34  0.1 M Ammonium thiocyanate, 0.1 M Tris (pH 8.0), 20 % PEG 8000 
35  0.1 M Ammonium thiocyanate, 0.1 M Tris (pH 8.0), 21 % PEG 8000 
36  0.1 M Ammonium thiocyanate, 0.1 M Tris (pH 8.0), 22 % PEG 8000 
37  0.72 M Lithium sulphate monohydrate, 0.1 M Bis-Tris Propane (pH 7.0) 
38  0.76 M Lithium sulphate monohydrate, 0.1 M Bis-Tris Propane (pH 7.0) 
39  0.80 M Lithium sulphate monohydrate, 0.1 M Bis-Tris Propane (pH 7.0) 
40  0.84 M Lithium sulphate monohydrate, 0.1 M Bis-Tris Propane (pH 7.0) 
41  0.88 M Lithium sulphate monohydrate, 0.1 M Bis-Tris Propane (pH 7.0) 
42  0.92 M Lithium sulfate monohydrate, 0.1 M Bis-Tris Propane (pH 7.0) 
43  1.2 M Lithium sulfate monohydrate, 0.1 M Tris (pH 8.5) 
44  1.3 M Lithium sulfate monohydrate, 0.1 M Tris (pH 8.5) 
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45  1.4 M Lithium sulfate monohydrate, 0.1 M Tris (pH 8.5) 
46  1.5 M Lithium sulfate monohydrate, 0.1 M Tris (pH 8.5) 
47  1.6 M Lithium sulfate monohydrate, 0.1 M Tris (pH 8.5) 
48  1.7 M Lithium sulfate monohydrate, 0.1 M Tris (pH 8.5) 
49  0.08 M Lithium chloride, 0.1 M Tris (pH 8.0), 20 % PEG 8000 
50  0.09 M Lithium chloride, 0.1 M Tris (pH 8.0), 20 % PEG 8000 
51  0.1 M Lithium chloride, 0.1 M Tris (pH 8.0), 20 % PEG 8000 
52  0.11 M Lithium chloride, 0.1 M Tris (pH 8.0), 20 % PEG 8000 
53  0.12 M Lithium chloride, 0.1 M Tris (pH 8.0), 20 % PEG 8000 
54  0.13 M Lithium chloride, 0.1 M Tris (pH 8.0), 20 % PEG 8000 
55  0.08 M Ammonium thiocyanate, 0.1 M Tris (pH 8.0), 20 % PEG 8000 
56  0.09 M Ammonium thiocyanate, 0.1 M Tris (pH 8.0), 20 % PEG 8000 
57  0.10 M Ammonium thiocyanate, 0.1 M Tris (pH 8.0), 20 % PEG 8000 
58  0.11 M Ammonium thiocyanate, 0.1 M Tris (pH 8.0), 20 % PEG 8000 
59  0.12 M Ammonium thiocyanate, 0.1 M Tris (pH 8.0), 20 % PEG 8000 
60  0.13 M Ammonium thiocyanate, 0.1 M Tris (pH 8.0), 20 % PEG 8000 
61  0.1 M Calcium acetate, 0.1 M Bis-Tris Propane (pH 7.0), 17 % (w/v) PEG 4000 
62  0.1 M Calcium acetate, 0.1 M Bis-Tris Propane (pH 7.0), 18 % (w/v) PEG 4000 
63  0.1 M Calcium acetate, 0.1 M Bis-Tris Propane (pH 7.0), 19 % (w/v) PEG 4000 
64  0.1 M Calcium acetate, 0.1 M Bis-Tris Propane (pH 7.0), 20 % (w/v) PEG 4000 
65  0.1 M Calcium acetate, 0.1 M Bis-Tris Propane (pH 7.0), 21 % (w/v) PEG 4000 
66  0.1 M Calcium acetate, 0.1 M Bis-Tris Propane (pH 7.0), 22 % (w/v) PEG 4000 
67  0.08 M Calcium acetate, 0.1 M Bis-Tris Propane (pH 7.0), 20 % (w/v) PEG 4000 
68  0.09 M Calcium acetate, 0.1 M Bis-Tris Propane (pH 7.0), 20 % (w/v) PEG 4000 
69  0.10 M Calcium acetate, 0.1 M Bis-Tris Propane (pH 7.0), 20 % (w/v) PEG 4000 
70  0.11 M Calcium acetate, 0.1 M Bis-Tris Propane (pH 7.0), 20 % (w/v) PEG 4000 
71  0.12 M Calcium acetate, 0.1 M Bis-Tris Propane (pH 7.0), 20 % (w/v) PEG 4000 
72  0.13 M Calcium acetate, 0.1 M Bis-Tris Propane (pH 7.0), 20 % (w/v) PEG 4000 
73  0.16 M Manganese chloride, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 11 % 
(w/v) PEG 8000, 20 % (v/v) glycerol 
74  0.16 M Manganese chloride, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 12 % 
(w/v) PEG 8000, 20 % (v/v) glycerol 
75  0.16 M Manganese chloride, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 13 % 
(w/v) PEG 8000, 20 % (v/v) glycerol 
76  0.16 M Manganese chloride, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 % 
(w/v) PEG 8000, 20 % (v/v) glycerol 
77  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 15 
% (w/v) PEG 8000, 20 % (v/v) glycerol 
78  0.16 M Manganese chloride, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 16 % 
(w/v) PEG 8000, 20 % (v/v) glycerol 
79  0.16 M Manganese chloride, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 % 
(w/v) PEG 8000, 17 % (v/v) glycerol 
80  0.16 M Manganese chloride, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 % 
(w/v) PEG 8000, 18 % (v/v) glycerol 
81  0.16 M Manganese chloride, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 % 
 95 
 
(w/v) PEG 8000, 19 % (v/v) glycerol 
82  0.16 M Manganese chloride, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 % 
(w/v) PEG 8000, 20 % (v/v) glycerol 
83  0.16 M Manganese chloride, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 % 
(w/v) PEG 8000, 21 % (v/v) glycerol 
84  0.16 M Manganese chloride, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 % 
(w/v) PEG 8000, 22 % (v/v) glycerol 
85  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 23 % (v/v) glycerol 
86  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 24 % (v/v) glycerol 
87  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 25 % (v/v) glycerol 
88  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 26 % (v/v) glycerol 
89  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 27 % (v/v) glycerol 
90  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 28 % (v/v) glycerol 
91  0.16 M Manganese chloride, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 % 
(w/v) PEG 8000, 23 % (v/v) glycerol 
92  0.16 M Manganese chloride, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 % 
(w/v) PEG 8000, 24 % (v/v) glycerol 
93  0.16 M Manganese chloride, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 % 
(w/v) PEG 8000, 25 % (v/v) glycerol 
94  0.16 M Manganese chloride, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 % 
(w/v) PEG 8000, 26 % (v/v) glycerol 
95  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 27 % (v/v) glycerol 
96  0.16 M Manganese chloride, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 % 
(w/v) PEG 8000, 28 % (v/v) glycerol 
97  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 11 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Leu-Pro 
98  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 12 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Leu-Pro 
99  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 13 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Leu-Pro 
100  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Leu-Pro 
101  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 15 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Leu-Pro 
102  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 16 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Leu-Pro 
103  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 17 % (v/v) glycerol, 10 mM Leu-Pro 
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104  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 18 % (v/v) glycerol, 10 mM Leu-Pro 
105  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 19 % (v/v) glycerol, 10 mM Leu-Pro 
106  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Leu-Pro 
107  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 21 % (v/v) glycerol, 10 mM Leu-Pro 
108  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 22 % (v/v) glycerol, 10 mM Leu-Pro 
109  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 11 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro 
110  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 12 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro 
111  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 13 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro 
112  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro 
113  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 15 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro 
114  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 16 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro 
115  0.16 M Calcium acetate hydrate , 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 17 % (v/v) glycerol, 10 mM Pro 
116  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 18 % (v/v) glycerol, 10 mM Pro 
117  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 19 % (v/v) glycerol, 10 mM Pro 
118  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro 
119  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 21 % (v/v) glycerol, 10 mM Pro 
120  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 22 % (v/v) glycerol, 10 mM Pro, 10 mM Arg 
121  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 11 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Arg 
122  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 12 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Arg 
123  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 13 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Arg 
124  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Arg 
125  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 15 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Arg 
126  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 16 
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% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Arg 
127  0.16 M Calcium acetate hydrate , 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 17 % (v/v) glycerol, 10 mM Pro, 10 mM Arg 
128  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 18 % (v/v) glycerol, 10 mM Pro, 10 mM Arg 
129  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 19 % (v/v) glycerol, 10 mM Pro, 10 mM Arg 
130  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Arg 
131  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 21 % (v/v) glycerol, 10 mM Pro, 10 mM Arg 
132  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 22 % (v/v) glycerol, 10 mM Pro, 10 mM Arg 
133  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 11 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Leu 
134  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 12 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Leu 
135  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 13 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Leu 
136  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Leu 
137  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 15 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Leu 
138  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 16 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Leu 
139  0.16 M Calcium acetate hydrate , 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 17 % (v/v) glycerol, 10 mM Pro, 10 mM Leu 
140  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 18 % (v/v) glycerol, 10 mM Pro, 10 mM Leu 
141  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 19 % (v/v) glycerol, 10 mM Pro, 10 mM Leu 
142  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Leu 
143  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 21 % (v/v) glycerol, 10 mM Pro, 10 mM Leu 
144  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 22 % (v/v) glycerol, 10 mM Pro, 10 mM Leu 
145  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 11 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Phe 
146  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 12 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Phe 
147  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 13 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Phe 
148  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Phe 
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149  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 15 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Phe 
150  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 16 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Phe 
151  0.16 M Calcium acetate hydrate , 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 17 % (v/v) glycerol, 10 mM Pro, 10 mM Phe 
152  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 18 % (v/v) glycerol, 10 mM Pro, 10 mM Phe 
153  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 19 % (v/v) glycerol, 10 mM Pro, 10 mM Phe 
154  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 20 % (v/v) glycerol, 10 mM Pro, 10 mM Phe 
155  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 21 % (v/v) glycerol, 10 mM Pro, 10 mM Phe 
156  0.16 M Calcium acetate hydrate, 0.08 M Sodium cacodylate trihydrate (pH 6.5), 14 
% (w/v) PEG 8000, 22 % (v/v) glycerol, 10 mM Pro, 10 mM Phe 
 
 
